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Role of Stat3 in Keratinocyte Stem Cells During Skin Tumorigenesis 
Dharanija Rao, M.S. 
Supervisory Professor: John DiGiovanni, Ph.D  
 
STATs play crucial roles in a wide variety of biological functions, 
including development, proliferation, differentiation, migration and in cancer 
development. In the present study, we examined the impact of Stat3 deletion or 
activation on behavior of keratinocytes, including keratinocyte stem cells 
(KSCs). Deletion of Stat3 specifically in the bulge region of the hair follicle 
using K15.CrePR1 X Stat3fl/fl mice led to decreased tumor development by 
altering survival of bulge region KSCs. To further understand the role of KSCs 
in skin tumorigenesis, K5.Stat3C transgenic (Tg) mice which express a 
constitutively active/dimerized form of Stat3 called Stat3C via the bovine 
keratin 5 (K5) promoter were studied. The number of CD34 and α6 integrin 
positive cells was significantly reduced in Tg mice as compared to non-
transgenic (NTg) littermates. There was a concomitant increase in the 
progenitor populations (Lgr-6, Lrig-1 and Sca-1) in the Tg mice vs. the stem cell 
population (CD34 and Keratin15). To investigate the mechanism underlying the 
increase in the progenitor population at the expense of bulge region KSCs we 
examined if Stat3C expression was involved in inducing migration of the bulge 
region KSCs. There was altered β-catenin and α6-integrin expression in the 
hair follicles of Tg mice, which may have contributed to reduced adhesive 
interactions between the epithelial cells and the basement membrane 
facilitating migration out of the niche. To further study the effect of Stat3 on 
differentiation of keratinocytes we analyzed the epidermal keratinocytes in 
K5.Cre X Stat3fl/fl mice. There was an increase in the expression of epidermal 
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differentiation markers in the Stat3 knockout mice. These data suggest that 
deletion of Stat3 in the epidermis and hair follicle induced differentiation in 
these cells. Preliminary studies done with the BK5.Stat3C mouse model 
suggests that multiple hair follicle stem/progenitor populations may be involved 
in skin tumor development and progression in this model of skin tumorigenesis. 
Overall, these data suggest that Stat3 plays an important role in differentiation 
as well as migration of keratinocytes and that these effects may play a role 
during epithelial carcinogenesis. 
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Chapter 1 
 
Mouse Skin 
Mouse skin is made of three layers that include the epidermis (the external 
epithelium), dermis (connective tissue layer) and the hypodermis (layer of adipose 
tissue). In addition, there are a number of supportive appendages that include hair 
follicles and sebaceous glands. The epidermis is further subdivided into the basal and 
the suprabasal epidermis. During embryonic development, ectodermal cells form the 
epidermis and its various layers, which are required to fulfill its barrier function. A switch 
marked by the expression of cytokeratin K5/K14 to K1/K10 indicates that the cell has 
left the basal layer and committed to differentiate terminally. The epidermal basal cells 
maintain a layer of proliferative cells that may contribute to the maintenance of the 
interfollicular epidermis (IFE). In addition, there are several stem/progenitor cell 
populations that are known to be present in the hair follicle which have proliferative 
capacity (1).   
 
Mouse Hair Follicle  
In mice, hair follicle morphogenesis is completed between postnatal day 1 and 
8. During this phase a series of epithelial to mesenchymal transitions occur where the 
hair follicle reaches a critical size and subsequently enters into a degenerative phase 
called catagen followed by a resting stage called telogen and then the growing stage 
called anagen (2). Hair follicles go through these phases of degeneration and regrowth 
called the hair cycle.   Multipotent stem cells located in the bulge region of the hair 
follicles are known to contribute to this cycle of growth and regeneration. The bulge 
region stem cells have been marked by several different methods one of which includes 
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their ability to retain Bromodeoxyuridine (BrdU) during long term pulse chase 
experiments called label retaining cell analyses (3). In addition to being label retaining 
cell (LRC), bulge region stem cells are also identified by surface expression of markers 
CD34 and α6-integrin (4, 5). The cells of the hair follicle have been now known to 
express multiple other markers that include Keratin-15 (6) MTS24/Plet-1 (7), Lrig-1 (8), 
Lgr5 (9), Lgr6 (10) and Sca-1 (11). These various cell populations have been shown to 
possess colony forming ability in vitro and regenerative potential in a number of in vivo 
experimental settings. Among all these cell populations, the bulge region stem cells 
have the ability to differentiate into all epidermal cell lineages when transplanted into 
immuno-deficient mice. It has been shown that while under normal physiological 
conditions bulge region stem cells contribute to maintenance of homeostasis of the 
populations in the hair follicle especially those below the sebaceous gland, they do not 
maintain the sebaceous gland and the inter-follicular epidermis (IFE). However, during 
pathological conditions or wounding, bulge region stem cells contribute to the repair 
machinery to ensure homeostasis (6, 12, 13, 9). 
In addition, to these stem/ progenitor populations seen in the hair follicle of mice 
there are stem cells that exist in the interfollicular epidermis and are called epidermal 
proliferative units. These stem cells have been shown to contribute to various other 
lineages other than the epidermis, which include the hair follicle and the sebaceous 
gland (14). 
 
Stem/Progenitor Cell Populations in the Mouse Hair Follicles 
CD34 
The cells in the bulge region of the hair follicle are marked by the expression of 
the hematopoietic stem cell marker CD34 (5). The protein CD34 is a membrane bound 
receptor, which consists of an extracellular, membrane bound and an intracellular 
domain. The extracellular mucin domain is rich in amino acid residues like serine, 
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threonine and proline and consists of O-glycosylated and sialylated residues. In addition 
to cysteine containing globular domains, it also contains putative sites for N-
glycosylation. The extracellular domain is attached to the transmembrane domain by 
means of a juxtamembrane stalk. The intracellular domain is a short cytoplasmic tail, 
which has putative sites for phosphorylation and C-terminal PDZ domain docking sites 
DTEL and DTHL. 
There are a number of proposed binding partners of CD34. In hematopoietic 
progenitor cells CD34 interacts with CRKL, which is a member of the Crk family of 
adaptor proteins. Crk proteins contain one SH2 and two SH3 domains and enable 
intracellular signaling cascades in proteins that do not possess intrinsic kinase activity. 
Direct binding sites for CRKL on CD34 has not been determined; it is dependent on a 
highly conserved intracellular juxtamembrane sequence that is present in both of the 
CD34 isoforms. Some of the known functions of CD34 protein are enhancing 
proliferation and blocking differentiation promoting lymphocyte adhesion, blocking cell 
adhesion, trafficking of hematopoietic cells and cell morphogenesis (15, 16, 17). 
 
Keratin-15 
Keratin-15 (K15), a type I cytokeratin which has no type II binding partner. It is 
expressed in a number of epithelia including sebaceous glands, outer root sheath 
(ORS), hair follicle (HF), adult epidermis, tongue, stomach, bronchial and cervical 
epithelia. It was first seen in a subset of epidermal basal cells and overlying periderm at 
E12.5 and then throughout the basal layer of epidermis by E15.5 and beyond. Its 
expression in the murine hair follicle follows the leading edge with positive cells 
restricted to the ORS. K15 expression is downregulated in hyperproliferative conditions 
like psoriasis. After 12 hr of 12-O-tetradecanoylphorbol-13-acetateTPA treatment, it is 
retained in the basal layer of the epidermis, after 24 hr it is found to be associated with 
the suprabasal compartment and is seen in the basal epidermis again at 96 hr. following 
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TPA treatment. A downregulation of the number of K15 positive epidermal basal cells 
was seen 2 weeks following DMBA-TPA treatment. Sporadic K15 positive cells were 
found in the basal and suprabasal compartments 6 weeks after TPA treatment. Overall, 
K15 expression progressively decreases ultimately leading to no visible expression in 
the epidermal structures infiltrating the dermis throughout 12 weeks of DMBA-TPA 
treatment (18). 
 
MTS24/Plet1 
MTS24 is an epithelial progenitor cell marker in the thymus. It contains a 
glycoprotein with a peptide backbone of 80kDa. During early embryonic development of 
thymus, a large proportion of MTS24 positive thymic epithelial cells were found to be 
expressed in a rare subset of epithelial cells in the adult thymus. Transplantation of 
MTS24 positive cells gives rise to a fully functional thymic epithelium (7, 19). It is 
expressed in the upper isthmus area of the mouse hair follicles, which is also marked by 
CD34 negative and α6-integrin low cells. 
 
Lgr 
Lgr stands for Leucine rich G protein coupled receptor. Lgr4, Lgr5 and Lgr6 are 
all found to be expressed in different although overlapping regions of the murine hair 
follicle (10). Lgr5 is an intestinal stem call marker, which encodes a large G protein 
coupled receptor characterized by a large leucine rich extracellular domain and seven 
transmembrane domains. It is very closely related to thyroid stimulating hormone (TSH), 
follicle stimulating hormone  (FSH) and luteinizing hormone (LH), which have 
glycoprotein ligands. It is a Wnt target gene and often overexpressed in colon cancer. 
Lgr-5 demonstrates a complex expression pattern during embryogenesis, however, its 
expression in most tissues subsides around birth. In adults, rare scattered cells are 
seen in intestine, HF, eye, brain, mammary gland, reproductive organs, skin and 
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stomach. Mice deficient in Lgr-5 showed malformation of the tongue and lower jaw 
causing newborns to swallow air, leading to early neonatal death. In Lgr-5 GFP mice X 
APCmin mice, Lgr-5 GFP expression was found to be restricted to a small number of 
cells in large adenomas, which are considered tumor-initiating cells in colon (9, 20). 
 
Lrig-1 
Lrig-1 stands for Leucine rich repeats and immunoglobulin domain protein-1. It is 
a transmembrane protein that interacts with and decreases signaling by ErbB growth 
factor receptor. It is a Myc target gene and is required for epidermal homeostasis. 
Deletion of Lrig-1 led to epidermal hyperplasia in mouse skin whereas depletion of Lrig-
1 in cultured human keratinocytes caused increased proliferation associated with stem 
cell expansion. In cultured keratinocytes, Lrig-1 was found to negatively regulate EGF 
induced Erk MAPK signaling and decreased Myc transcription, RNA and protein levels. 
Human Lrig-1 gene is located at Chr 3p14 and is frequently deleted in human cancers, 
suggesting that it might be a tumor suppressor. Lrig-1 disrupted mice show psoriatic 
epidermal hyperplasia in the skin of the face and the tail. It is found to be expressed in 
the junctional zone region where the sebaceous gland connects to the hair follicle. Its 
expression overlaps with the expression of Lgr6 (8). 
 
Sca-1 
Sca-1 is an 18kDa mouse glycosyl phosphatidylinositol anchored cell surface 
protein of the Ly6 family. These cysteine rich GPI-APs contain 2-3 protruding fingers 
and are localized to lipid rafts of plasma membrane. Sca-1 expression is regulated in a 
complex fashion in hematopoietic ontology. All HSCs in Ly6.2 strains like C57Bl/6 
express Sca-1 where as only 25% HSCs express Sca-1 in Ly6.1 strains like BALB/c. 
Outside the hematopoietic system, Sca-1 is expressed by stem/progenitor or 
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differentiated cells in the bone, mammary gland, prostate, skeletal system, heart, 
dermis, liver and lung.  
With the exception of traditional flow cytometry methods of detecting Sca-1 have 
posed many challenges. Redundancy among Ly6 genes prevents Northern analysis 
and requires stringent RT or qPCR conditions. Various Sca-1 Abs are less than ideal for 
Western analysis and immunostaining. Recently 4 mouse models have become 
available which include Sca-1 LacZ, Sca-1 GFP transgenic mouse model, Sca-1 eGFP 
knock in transgenic mouse and Sca-1 null mouse model which may help in unveiling the 
role of Sca-1 in various tissues. 
Sca-1 is also upregulated in a variety of murine tumors, consistent with the 
cancer stem cell theory. In several murine tumors, higher levels of Ly6 family protein 
expression have been correlated with a higher malignancy phenotype (21). In the 
prostate, Akt overexpression in Sca-1+ cells initiates tumorigenesis, with cancer 
progression correlating with increased Sca-1+ cells (22). Sca-1 enhances mammary 
tumorigenicity by disrupting GDF-10 dependent TGF-β signaling (23). 
Although Sca-1 was discovered more than a decade ago, the definitive role of 
Sca-1 in stem cells has still not been identified. Receptor-ligand interactions underlie 
the function of many Ly6 proteins, potentially mediating cell-cell adhesion and signaling. 
Recent work done using Sca-1 null mice to study lymphocyte proliferation suggests a 
cell-signaling role for Sca-1 (24). In the muscle Sca-1 appears to downregulate muscle 
cell proliferation, thereby maintaining a pool of functional progenitor cells for muscle 
homeostasis and repair (25). Sca-1 could potentially coregulate a variety of different 
signaling pathways by modulating lipid rafts composition via weak protein protein 
interactions that sequester key signaling molecules. Sca-1 could potentially play a role 
in signaling pathways involving receptor tyrosine kinases and Src family kinases. 
Overall, current evidence suggests that Sca-1 may serve as the negative regulator of 
Src family kinase signaling (26).   
	   7	  
 
 
 
 
 
 
Ref: (12) 
Figure 1: Murine Hair Follicle During Anagen and Telogen.  Hair follicle bulge region 
is marked by expression of CD34/α6-integrin and Keratin-15. MTS24 labels the upper 
isthmus. Lrig-1/Lgr6 labels the junctional zone and Sca-1 marks the infundibulum area 
of the hair follicle. Lgr5 expression is seen both in the bulge region as well as the 
dermal papilla region.  Reproduced with the permission of the journal Developmental 
Cell. Rights and permissions included in the copyright section 
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Normal vs. Cancer Stem Cells 
For many years clonal evolution model was the conventional model to define 
and study tumor development. According to the Clonal evolution hypothesis, a genetic 
alteration or a mutation gives a cell a selective growth advantage over the other cells in 
the same microenvironment to act like a tumor cell.  These tumor cells acclimatize to 
the changes in the tumor microenvironment (which is subject to constant change in a 
tumor), which helps them to persist and perpetuate the cancer (27).  
The cancer stem cell hypothesis on the other hand, states that only the cell at 
the apex of the hierarchy has the ability to proliferate extensively and form new tumors. 
In adult tissues, the tissue specific stem cells, which have irreversibly committed to that 
particular lineage, are responsible for maintaining tissue homeostasis. It gives rise to 
the cells next in hierarchy, the progenitor or transit amplifying cells, which form the 
terminally differentiated cell. The terminally differentiated cells have a finite life span and 
have lost their ability to ceaseless proliferation (28).  
The term “Cancer Stem Cell’ has been very controversial especially when 
referring to solid tumors but is now referred to as the cell population that in a xenograft 
has the ability to regenerate a tumor in a serially diluted setting for several generations. 
The CSC hypothesis also supports the view cancer stem cell may be an adult tissue 
resident stem cell that underwent transformation or any other cell that gained stem cell 
properties in addition to the transformation event hence giving it the selective advantage 
of deregulated self-renewal potential and uncontrolled proliferative ability. This led some 
to believe that the progenitor cells, which possess the limited self renewal and 
replicative potential, in these tissues may also undergo genetic or environmental 
modifications to develop into a CSC. Although not very well accepted yet, there is also a 
possibility for the terminally differentiated cell to undergo a process of dedifferentiation 
to form a CSC adept with a high replicative ability. 
	   9	  
In skin tumors, the bulge region stem cells are known to be the putative target 
cells at least in the case of two-stage chemical carcinogenesis and UV carcinogenesis 
protocols. The main rationale behind this hypothesis is that skin being a rapidly 
proliferating tissue with a very high turnover rate does not allow for the epidermal cells 
to be targeted by the carcinogen and be available for long-term generation and 
maintenance of the skin tumor. Notably after TPA treatment (which induces a 
hyperproliferative response followed by differentiation) in the two-stage skin 
carcinogenesis protocol, even if the interfollicular epidermal cell got the hit /mutation by 
the carcinogen (DMBA) by the time TPA promotion ensues, the epidermis would 
undergo a full cycle of turn-over. Hence only the long-term resident tissue stem cells in 
the niche called the bulge region of the hair follicle would be able to effectively generate 
and maintain the developing skin tumor. These stem cells are known to express the 
hematopoietic stem cell marker CD34. The contribution of mouse hair follicle bulge 
region stem cells was further confirmed by studies from Morris RJ where CD34 
knockout and control mice were subjected to two-stage skin carcinogenesis and found 
to have a dramatic decrease in tumor incidence and multiplicity of skin tumors in the 
knock out mice when compared to the controls. Further studies including lineage-tracing 
studies may be required to study the migration of these cells from their niche to the 
upper areas of the hair follicle and skin as well as their role and contribution to tumor 
development. 
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        Ref: (29) 
Figure 2: Clonal Selection vs. Cancer Stem Cell Hypothesis.  (a). Clonal selection 
model is based on the underlying hypothesis that any cell can proliferate in a 
deregulated manner to give rise to new tumors whereas (b). Cancer stem cell 
hypothesis states that very rare stem cells that sit at the apex of the hierarchy and have 
undergone a transformation event are capable of extensive, uncontrolled proliferation to 
form tumors. Reproduced with the permission of the journal Nature. Rights and 
permissions included in the copyright section 
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JAK STAT Signaling Pathway 
 
Ref: (30) 
Figure 3: JAK-STAT Signaling Pathway:  The JAK-STAT signaling pathway is 
activated downstream of IL6, receptor tyrosine kinase or growth factor receptors and is 
followed by phosphorylation of Janus associated kinases which in turn phosphorylate 
Stats. Phosphorylation of Stats leads to their homo/heterodimerization followed by 
translocation into the nucleus where it carries out the transcription of its target genes. 
Reproduced with the permission of the journal Nature Reviews Immunology. Rights and 
permissions included in the copyright section 
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Signal Transducers and Activators of Transcription (Stats) 
Signal Transducers and Activators of Transcription (Stat) are proteins that get 
activated by extracellular signaling proteins some of which include growth factors, 
cytokines as well as various peptides. Cell surface mediated receptor activation causes 
the phosphorylation of tyrosine kinases like Janus associated kinase (JAK) that 
provides docking sites for Src homology (SH2) domain for binding of Stats. The 
reciprocal interaction between the SH2 domain of the monomer with the phosphorylated 
tyrosine of the other monomer results in the formation of a functional Stat dimer. The 
Stat proteins are thus recruited to JAKs and are phosphorylated at their single tyrosine 
residues. The phosphorylated Stats dimerize, translocate to the nucleus and drive 
transcription of their target genes.  
While activation of Stats downstream of ligand-induced activation is linked to 
functions like differentiation and growth regulation, constitutive activation of Stats is 
often seen to lead to deregulated growth (31). There are seven different Stat proteins, 
which include Stat1 through Stat6. Stat5 has isoforms Stat5a and Stat5b. Stat1, Stat3, 
Stat4, Stat5a and Stat5b all form homodimers but Stat1 and Stat2, and Stat1 and Stat3 
can form heterodimers as well.  
 
Structure of Stat Proteins 
Stats have an amino terminal and a carboxy terminal domain. Towards the 
carboxyl terminus is the transactivation domain (TAD), which contains the tyrosine 
residues that upon phosphorylation may play an important role in a number of 
biological/signaling functions. The SH2 domain provides a docking site for other 
proteins with SH2 domains for protein-protein interaction. The DNA binding domain is 
present in the center of the molecule. This domain interacts with both the major as well 
as the minor groove of the DNA strand. Towards the amino terminus is a helical coiled 
	   13	  
coil domain, which may be involved in extensive protein-protein interactions. In addition, 
there is a linker domain of unknown function, which has a highly conserved structure 
(32). 
 
Functional Domains of STAT Proteins 
Research on the structure and function by methods like site directed 
mutagenesis helped determine the function of the various domains of Stat proteins. The 
helical domains near residue 130 are the regions where interactions with other proteins 
occur. The DNA binding domain extends from residue 300-500. The linker domain is 
present between the residues 500-575. This is followed by the SH2 domain and the 
transactivation domain, which contains the critical tyrosine residue, which gets 
phosphorylated at the 705 site and is important to execute the transcriptional roles of 
the Stat  (Stat3) proteins. COOH terminal 38 amino acids in Stat1 and 75 amino acids in 
Stat3 have ben implicated in initiating their transcriptional activation. Serine 727 is 
present towards the COOH terminus and is now known to mediate both transcriptional 
as well as non-transcriptional roles of Stat proteins. Not only are both carboxyl as well 
as the amino terminal ends of the Stat proteins involved in facilitating the transcriptional 
function of Stats but they are also involved in interacting with other proteins including, 
MCM, ICAM, CEBP and CBP/p300 where they engage in the transcriptional machinery 
of the cell (31). 
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Ref:(32) 
 
Figure 4: Structure of STATs:  (a). Crystal structure of Stats showing the NH2, DNA 
binding, coiled coil, linker, SH2 and transactivation domain. (b). Stats have an amino 
terminal and a carboxyl terminal domain with the phosphorylation sites being closer to 
the carboxyl terminus. Reproduced with the permission of the journal Nature Reviews 
Molecular Cell Biology. Rights and permissions included in the copyright section 
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Biological Functions of Stat3 in Various Tissues 
 
Stat3 knockout mice are embryonically lethal so its role in various tissues has 
been identified by generating tissue specific animal models. Conditional gene targeting 
in a tissue specific manner by generating various mouse models has helped elucidate 
the roles of Stats in specific tissues. In the skin, disruption of Stat3 impairs hair cycle, 
migration of keratinocytes and wound healing. In the T lymphocytes and neurons it 
impairs cell survival. In monocytes, neutrophils and granulocytes Stat3 regulates 
processes like inflammatory response and proliferation and in the mammary epithelium 
it can result in a deregulated apoptotic response (32). 
 
New Roles of Stat3 
The nuclear transcriptional roles of Stat3 are very well known. Recently, a 
number of reports have shown that Stat proteins perform additional functions in 
response to cytokine stimulation. These include its function as a transcription factor 
even in its unphosphorylated form especially in cancers and in maintaining 
heterochromatin stability. A study by Yang et al., showed that unphosphorylated Stat3 
can respond to IL-6, drive the transcription of its targets and bind to other proteins, one 
of which was NFkB (33). Another pioneering study published in Science, showed that 
Stat3 is functional in the mitochondria of cultured cells and primary tissues, including 
heart and lung, where it is required for the optimal function of the electron transport 
chain and maintaining cellular respiration (34). Studies by Timofeeva et al., showed that 
unphosphorylated Stat3 is involved in maintaining genome/chromatin organization by 
recognizing and binding to specific DNA structures, which are important for chromatin 
organization (35). 
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Negative regulators of Stat signaling 
Cytoplasmic tyrosine phosphatases  
SHP-1, SHP-2 or PTP1B are some of the negative regulators of Stat proteins 
and are involved in dephosphorylation of the tyrosine residues, which are important for 
the function of the Stat proteins. (32). Tyrosine phosphorylation states of the proteins in 
the JAK-STAT signaling cascade are maintained by a delicate balance between the 
activities of the kinases and the phospahatases called the protein tyrosine 
phosphatases (PTPases). SHP-1 and SHP-2 are SH2 domain containing PTPases that 
interact with and regulate JAK2 in response to cytokine receptor activation. 
Downregulation of JAK/STAT signaling occurs through direct dephosphorylation of the 
JAK2 kinase by SHP-1. While SHP-1 is a negative regulator of mitogenic signaling, 
SHP-2 phosphatase leads to a stimulatory role of the growth factor receptor 
downstream signaling. SHP-2 appears to interact directly with the mitogenic receptor 
via its two SH2 domains (36). 
 
SOCS  
SOCS-1 belongs to the SOCS family of regulators of cytokine signaling. It was 
reported to be involved in a negative feedback loop in signaling. Signaling cascades 
induced by cytokines like interleukin-6 (IL-6), IL-4, leukemia inhibitory factor (LIF), 
oncostatin M, interferon (IFN), and growth hormones are suppressed by the activation 
of this protein. The mechanism underlying this function of the SOCS-1 protein is, in part, 
through direct interaction with active JAKs where it binds to the activation loop of JAK 
kinases through its SH2 domain, thereby blocking subsequent downstream signaling of 
the Jak/Stat pathway (37, 38).  
Another role for SOCS-1 is by mediating proteasomal degradation of its 
associated proteins. SOCS-1 has a COOH terminal homology domain SOCS box. This 
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SOCS is an ubiquitin ligase for JAK2 and targets JAK2 for ubiquitination and 
proteasomal degradation. (39, 40). 
Although SOCS-1 has been reported to be a tumor suppressor gene, its function 
in tumor development and progression varies in a cell and/or a tissue specific manner. 
Regulation of Jak2 through the Ubiquitin-Proteasome pathway involves phosphorylation 
of Jak2 on Y1007 and interaction with SOCS-1 (41).  Ectopic expression of SOCS-1 
can also inhibit the oncogenic role of the KIT receptor and v-ABL. It also showed 
reduced metastasis of BCR-ABL transformed cells (42). However, in cancers like 
melanoma, SOCS-1 marks tumor progression rather than acting as a tumor suppressor 
gene (43). 
PIAS 
One way transcription factor regulation is achieved is by sumoylation (44). 
Protein Inhibitor of Activated Stats (PIAS) was reported to be a E3-type small ubiquitin 
like modifier (SUMO) ligase which inhibits the activity of Stat transcription factors in 
addition to modulating other pathways including Wnt signaling, p53 pathway and steroid 
hormone signaling. PIAS/SUMO pathway appears to manage transcriptional regulation 
by stimulating the attachment of the ubiquitin like SUMO modifier to the target proteins 
(45). 
 
Stat3 and Stem Cells 
Stat3 plays a critical role in maintaining the pluripotent stem cell phenotype as 
well as stem cell survival (46). Studies using an inducible, active Stat3 expression 
construct showed that Stat3 activation is sufficient to maintain embryonic stem (ES) 
cells in an undifferentiated state (47). Moreover, stable expression of a dominant 
negative Stat3 in ES cells induced differentiation even in the continuous presence of 
leukemia inhibitory factor (LIF) (48). Several previous studies reported that Stat3 
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activation is required for LIF-driven ES cell self-renewal (49). In addition, Stat3 appears 
to be one of the core regulators in mouse ES cells in addition to key stem cell regulators 
such as Oct4, Sox2 and Nanog (50). Together, these results suggest that activation of 
Stat3 may play an important role, in collaboration with other proteins, in regulating ES 
cell behavior. Although Stat3 activation has been shown to maintain cells in an 
undifferentiated state, Stat3 activation has also been shown to be associated with 
differentiation in specific cell types (51-54) 
 
Stat3 and Cancer 
Recently, there have been a number of reports elucidating the importance of 
Stat3 in regulating cell migration, motility and invasion in both physiological and 
pathological situations. Stat3 conditional knockout (KO) mouse enabled the study of the 
impact of Stat3 on various cell populations and tissues. Deletion of Stat3 in 
keratinocytes compromised the wound-healing process in skin and inhibited migration 
of cultured keratinocytes (55). A similar role of Stat3 in regulating cell migration has also 
been found in mouse embryonic fibroblasts (MEFs) and keloid-derived fibroblasts (56, 
57). In Drosophila, the JAK-STAT pathway has been shown to activate migratory and 
invasive behavior of ovarian epithelial cells in ovarian development (58). Stat3 has also 
been found to control cell movement during zebrafish gastrulation (59). In agreement 
with this finding, Stat3-knockout mice exhibited embryonic lethality during gastrulation 
(60). Furthermore, promotion of tumor invasion and metastasis by Stat3 has been 
widely reported in various cancers, including ovarian carcinoma, melanoma, bladder, 
pancreatic and prostate cancers (61-65). These data suggest that regulation of cell 
movement could be a fundamental function of Stat3. However, exactly how Stat3 
regulates cell migration remains largely unknown. Stat3 also plays a role in cell 
movement associated with gastrulation, a key step in early embryogenesis involving 
morphogenetic changes and the specification of cell fate (59). Keratinocytes that are 
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deficient in Stat3 show impaired growth factor dependent migration in culture in a cell 
autonomous manner (55). 
 
 
	   20	  
 
Two-stage Skin Carcinogenesis 
Multistage nature of epithelial carcinogenesis has been extensively studied 
using the two-stage model of mouse skin carcinogenesis. In addition to the cellular, and 
biochemical components that are involved in epithelial carcinogeneiss this model 
helped identify the molecular mechanisms associated with the various stages of 
carcinogenesis (66). In this model, tumor development occurs via three distinct stages: 
initiation, promotion and progression (66). For tumor initiation, one of the most 
commonly used genotoxic carcinogens, (7,12-dimethylbenz[a]anthracene (DMBA)), 
induces a mutation in a critical gene or genes by binding with DNA and forming specific 
carcinogen-DNA adducts that are not repaired or repaired incorrectly. The Ha-ras gene 
is now known to be a primary target gene for the initiation stage in this carcinogenesis 
model and is mutated following exposure to DMBA (66). Following initiation, tumor 
promotion occurs by repeatedly applying a non-mutagenic tumor promoter, such as 12-
O-tetradecanoylphorbol-13-acetate (TPA), which affects gene expression and 
stimulates epidermal cell proliferation. Tumor promotion by TPA results in the clonal 
expansion of initiated cells developing premalignant papillomas. Progression of 
papillomas into malignant squamous cell carcinomas (SCCs) occurs stochastically and 
is independent of tumor promoter treatment. An increased probability of genetic 
alterations in the expanded population of initiated cells and subsequent selection 
converts papillomas to SCCs (66, 67). Numerous gene expression changes are 
believed to drive progression in this model. A gene signature that is associated with 
high risk for malignant conversion of papillomas was identified. This gene expression 
profile was identified in a two-stage skin carcinogenesis protocol using SENCAR mice 
and distinguished early stage papillomas likely to convert to SCC from those papillomas 
with a low probability of malignant conversion. 
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Ref: (68) 
 
Figure 5: Two-stage skin carcinogenesis:  Two-stage chemical carcinogenesis 
allows for studying specific stages of tumor development in mouse skin which can be 
broadly categorized into three main phases. The first stage called the initiation is when 
a carcinogenic or sub-carcinogenic dose of a chemical carcinogen is applied as an 
initiating agent. This induces a mutation (e.g. in the Ras gene if the initiating carcinogen 
is DMBA) in the putative target cell/tumor initiating cell, which is now capable of giving 
rise to the tumor. The next stage is the promotion phase, which gives rise to a pre-
malignant lesion called the papilloma that has the potential to advance to the malignant 
or the invasive stage of cancer called the progression phase. Reproduced with the 
permission of the journal Nature Protocols. Rights and permissions included in the 
copyright section 
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UV Skin Carcinogenesis 
UV radiation can be responsible for generating pre-malignant and malignant skin 
lesions. It is a complete carcinogen and can induce DNA mutations/damage that results 
in altered expression and function of important cell cycle regulators like p53. Epidermal 
cells are known to be the main targets of UVB radiation. In mouse skin, UVB radiation 
leads to formation of “sunburn cells” which are keratinocytes that have undergone 
apoptosis. This event may be called a transformation event, which may contribute to 
uncontrolled growth of cells where there are unrepairable defects in genes that regulate 
cell cycle and cell proliferation. After UV irradiation, the keratinocytes that survive 
undergo cell cycle arrest and will continue to stay in either G1 or G2 phase of the cell 
cycle. The repair machinery in the cell will be recruited to repair any UV induced DNA 
damage e.g. p53 (69). p53 mutations are one of the most common UV-induced 
alterations, which lead to deregulations of its downstream targets WAF1/CIP1 gene 
product, the p21 protein, which controls the cell cycle by regulating several cyclins and 
cyclin dependent kinases. 
 
Stat3 and Skin Tumorigenesis 
Stat3 is activated following treatment with different classes of tumor promoters 
including TPA, okadaic acid and chrysarobin (70). Both papillomas and SCCs 
generated by the two-stage skin carcinogenesis protocol showed increased expression 
as well as constitutive activation of Stat3. In addition, a series of experiments showed 
that the primary mechanism for activation of Stat3 in keratinocytes exposed to tumor 
promoters is through activation of EGFR. Further studies provide evidence that Stat3 is 
required for both initiation and promotion stages of epithelial carcinogenesis (71). In this 
regard, treatment with DMBA resulted in a significant increase in the number of 
epidermal cells undergoing apoptosis, especially those located in the bulge region of 
the hair follicles of the Stat3 deficient mice. Following topical application of TPA, while 
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the epidermis of control mice showed dramatic hyperplasia, Stat3 deficient mice did not 
show similar results. In these mice milder acanthosis with a significantly reduced 
epidermal BrdU labeling index was observed. The mechanism underlying the above 
observation pointed towards altered cell cycle regulation recovery of cyclin D1 and 
cyclin E was delayed and c-myc expression was persistently down-regulated in the 
epidermis of Stat3 deficient mice after topical TPA treatment compared to control mice. 
These results suggest that Stat3 plays a critical role in mediating G1 to S cell cycle 
progression and proliferation in murine keratinocytes following treatment with TPA. 
Subsequently, Stat3 deficient mice were found to be completely resistant to skin tumor 
development using a standard DMBA/TPA skin carcinogenesis bioassay. Additionally, 
the use of a decoy oligonucleotide which allows for the abrogation of Stat3 function also 
inhibited the growth of initiated keratinocytes possessing an activated Ha-ras  gene, 
both in vitro and in vivo (71). Finally, injection of Stat3 oligonucleotide decoy into skin 
papillomas induced regression, suggesting that constitutive activation of Stat3 is 
required for the proliferation and survival of tumor cells even at this early premalignant 
stage. In addition to its role in two-stage skin carcinogenesis, Stat3 also has a potential 
role in UVB-induced skin carcinogenesis. These studies were done using two different 
skin specific transgenic mice i.e., BK5.Stat3C, a gain of function, and K5.Cre X Stat3fl/fl   
a loss of function, transgenic mouse model respectively. When compared to the wild 
type mice, the epidermis of Stat3 deficient mice was found to be very sensitive to UVB 
induced apoptosis. On the other hand, the epidermis of BK5.Stat3C mice was 
significantly resistant to UVB induced apoptosis. In particular, the status of Stat3 
influenced the survival of UV-photoproduct containing cells, including those located in 
the bulge region of the hair follicles. Following UVB irradiation, there was a dramatic 
increase in the formation of skin tumors in BK5.Stat3C mice which included both 
incidence and multiplicity of skin tumors compared to the wild type controls. In contrast, 
Stat3 deficient mice were resistant to UVB skin carcinogenesis compared to wild type 
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controls. These studies demonstrate that Stat3 plays a critical role in the development 
of UVB induced skin tumors through its effects on both survival and proliferation of 
keratinocytes during carcinogenesis (72). 
 
Stat3 and Human Cancers 
After several years of research, it is well documented that Stat3 is constitutively 
activated or overexpressed in a number of human cancers including breast, prostate, 
head and neck SCC, pancreas and neuronal as well as hematopoietic cancers. 
Phospho-Stat3 (Tyr 705) was detected in invasive breast tumors compared to normal 
breast tissues. In addition, increased levels of phosphorylated Stat3 was associated 
with metastasis to regional lymph nodes (73). Higher levels of Stat3 activation 
correlated significantly with more malignant prostate tumors with higher Gleason 
scores. In a study done by Richard Jove’s group an analysis of 45 adenocarcinomas 
obtained at radial prostectomy showed 82% tumors to have elevated levels of 
constitutively active Stat3 compared to adjacent non-tumor prostate tissues (74). In 
head and neck SCC, STAT3 was found to alter cell cycle, prevent apoptosis, and 
mediate the proliferation and survival of tumor cells (75). Stat3 was reported to be 
constitutively activated in glioma and medulloblastoma tumors and that the activated 
protein localized predominantly to the tumor endothelial cells in the highly vascularized 
glioma tumors. In addition, studies indicate that the mechanism underlying the effects of 
Stat3 are mediated by VEGF in both neuronal and pancreatic cancers (76, 61). Stat3 
was also found to be constitutively activated in diverse tumor-infiltrating immune cells, 
and ablating Stat3 in hematopoietic cells triggered an intrinsic immune-surveillance 
system that inhibited tumor growth and metastasis (77). Overall, given its constitutive 
expression in a variety of human malignancies, Stat3 could be a critical target for 
therapy as well as an important chemo-preventive molecule. 
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Chapter 2 
 
Rationale 
 
 The primary goal of this research project is to understand the role of Signal 
Transducers and Activators of Transcription (STATs) particularly Stat3 in Keratinocyte 
Stem Cells (KSCs) during skin carcinogenesis. Previous studies from our lab through 
the use of a skin specific Stat3 knockout mouse model have shown that Stat3 was 
required for de novo skin tumor development during two-stage carcinogenesis. 
Mechanistic studies revealed that Stat3 was required for both initiation and promotion 
stages of skin carcinogenesis. During tumor initiation, further studies revealed that Stat3 
is required for survival of DNA damaged keratinocytes including those in the bulge 
region of the hair follicle. During tumor promotion, Stat3 appears to be required for 
proliferation and clonal expansion of initiated cells. Additional studies using a transgenic 
mouse model, BK5.Stat3C, have indicated that Stat3 may also play a role in tumor 
progression in this model of multistage epithelial carcinogenesis. Based on recent 
studies, Stat3 is also believed to play a particularly prominent role in KSC survival and 
proliferation. This project aims to examine Stat3 function specifically in the bulge region 
KSCs during homeostasis as well as during skin tumorigenesis and also explore the 
roles of specific Stat3 regulated genes that may help mediate its effects in bulge region 
KSCs. 
 
Hypotheses 
 
The hypothesis to be tested is that Stat3 is required for both survival of bulge region 
KSCs during initiation and for proliferation and survival of initiated bulge region KSCs 
during the promotion stage of epithelial carcinogenesis in mouse skin through regulation 
of specific genes involved in these processes. An additional hypothesis to be tested is 
that Stat3 is required during the progression phase and regulates specific genes that 
contribute to skin tumor progression.  
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Specific Aims 
Specific Aim 1 : To determine the impact of Stat3 deletion on the gene expression 
patterns, growth properties and survival of bulge region keratinocyte stem cells 
(KSCs) during skin carcinogenesis. 
In this aim, the effects of Stat3 deletion on properties of bulge region KSCs was 
evaluated. First, the number and growth properties as well as survival of bulge region 
KSCs was examined. The impact of Stat3 deletion on the levels (mRNA and protein) of 
various stem and progenitor cell populations in the skin, particularly the mouse hair 
follicle, was examined. For these studies, two mouse models were used, K15Cre.PR1 X 
Stat3fl/fl mice with specifically disrupted Stat3 in the bulge region of the hair follicle and a 
K5.Cre X Stat3fl/fl mouse model which deletes Stat3 from the basal layer of the 
epidermis as well as the outer root sheath (ORS) of the hair follicle. 
Specific Aim 2: To determine the impact of Stat3 activation on growth properties 
and survival of bulge region KSCs. 
In this aim, effects of Stat3 activation on properties of bulge region KSCs was 
evaluated. First, the number and growth properties of bulge region KSCs was 
examined. The number and levels (mRNA and protein) of various stem/progenitor cells 
in the murine hair follicle was examined. In addition, specific stem/progenitor 
populations that were regulated by Stat3 were analyzed.  
Specific Aim 3: To examine the role of Stat3 regulated genes (e.g. Sca-1) in skin 
tumor development and progression. 
In this aim, the role of Stat3 regulated genes especially involved in skin tumor 
development and tumor progression was further explored. In particular, the role Sca-1 
and Twist in rapid progression of skin tumors was observed in BK5.Stat3C transgenic 
mice during two-stage chemical carcinogenesis.  
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Chapter 3 
Material and Methods 
Mice  
BK5.Stat3C and K5.Cre+/- X Stat3fl/fl mice have been described previously. 7-9 week old 
mice were used for the catagen/telogen phase and 12-15 week old mice were used for 
the anagen phase analysis. Mouse dorsal skin was used for all experiments. NTg 
littermate controls were used for all experiments unless indicated otherwise. Both male 
and female mice were used for experiments. 
 
Label Retaining Cell (LRC) Analysis  
Ten-day-old pups were injected with BrdU (50µg/gm. body weight) i.p. every 12 hrs. for 
2 days. The chase period was continued for 70 days or until the mice reach anagen 
stage of the hair cycle. Mouse dorsal skins were harvested, fixed in formalin, embedded 
in paraffin and analyzed immunohistochemically for BrdU expression. The BrdU positive 
cell quantitation was done by two methods. Total number of follicles showing BrdU 
positive cells and number of BrdU positive cells/50 follicles in skin sections were 
quantified. At least 3 sections per animal and 3-5 animals per group were used for the 
analysis.  
 
Total hair follicle cell isolation and CFE  
Mouse dorsal skin was harvested by established protocols. Fat underlying the subcutis 
was mechanically scraped and the skins were incubated in dispase (5mg/ml) overnight 
at 4°C. Epidermis was harvested by mechanical scraping with a scalpel and the dermis 
was incubated in 1% collagenase for 2 hr at 37°C. The resulting solution was 
centrifuged at 300g and subsequently at 52 g for 5 min at 4°C. The supernatant was 
discarded and the pellet was pipetted in 0.25% Trypsin-EDTA multiple times and 
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incubated at 37°C for 12 minutes. The solution was pipetted multiple times and cells 
were strained through a 70 µm and 40 µm filters. Cells were analyzed for viability using 
Trypan Blue and total number of viable cells were counted using Heamatocytometer. 
 
Epidermal Keratinocyte isolation  
Mouse dorsal skin was harvested by established protocols. Fat underlying the subcutis 
was mechanically scraped and the skins were incubated in trypsin for 2 hrs at 37°C and 
30min at room temperature. Epidermis was harvested by mechanical scraping with a 
scalpel, minced with scissors and mechanically disrupted using a magnetic stirrer bar. 
The resulting solution was pipetted multiple times and cells were strained through a 70 
µm and 40 µm filters. Cells were analyzed for viability using Trypan Blue and total 
number of viable cells were counted using Heamatocytometer. 
 
Flow cytometry analysis  
Total hair follicle cells were isolated using the above protocol. The isolated total hair 
follicle cells were labeled with cell surface markers like biotin conjugated CD34 and PE-
α6-integrin. Cells were incubated on ice for 1hr. APC conjugated streptavidin was used 
as secondary antibody for 30 min on ice. For directly conjugated antibodies like CD34-
PE and Sca-1-FITC, cells were incubated with the antibody on ice for 1 hr Cells were 
fixed with a final concentration of 1% PFA and taken for analysis on BD FACS Calibur 
or BD FACS Aria. Data analysis was done using Cell Quest and FlowJo analysis 
programs. 
 
Immunostaining  
For formalin fixed, paraffin embedded sections, slides were deparaffinized using 
standard protocol. Sodium citrate was used for antigen retrieval. Slides were blocked 
using goat/donkey serum for 1hr at room temperature, incubated with primary antibody 
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for 1 hr at room temperature or 4°C overnight and subsequently with secondary 
antibody for 30 min at room temperature. For OCT frozen sections slides were air dried 
for 5-10 min, fixed with 4% paraformaldehyde for 10 min at room temperature, washed 
with Immunostain wash buffer (GeneTex), blocked with goat serum for 30-40 min at 
room temperature and immunostained with primary antibody for an hour and with 
appropriate secondary antibody for 30 min. Slides were mounted using mounting media 
(Vectashield with DAPI). 
 
Chromatin immunoprecipitation assay 
Mouse skin epidermis was cross-linked with formaldehyde followed by epidermal lysate 
preparation. Pierce ChIP kit was used for these experiments. Immunoprecipitation 
experiments were done using Stat3 (Cell Signaling Cat # 9132) and β-catenin (Cell 
Signaling Cat # 9562).  
 
RNA isolation from skin tumor 
Snap frozen individual or pooled skin tumors (papillomas or SCCs) were ground using a 
mortar and pestle in liquid nitrogen. The ground tissue was lysed in RNA lysis buffer 
(RLT-QIAGEN Kit) and homogenized using a 22-gauge needle and syringe. RNA was 
extracted using the protocols in the QIAGEN RNeasy Mini RNA Isolation Kit (74104). 
 
Quantitative Real Time Polymerase Chain Reaction 
Primary keratinocytes from BK5.Stat3C Tg and NTg mice or K5.Cre X Stat3fl/fl mice was 
used to isolate RNA. QIAGEN RNeasy Kit was used for RNA isolation. First strand 
synthesis using random primers (Invitrogen) was used for cDNA preparation. SYBR 
Green primers were used for quantitative real-time PCR, which was performed on the 
Applied Biosystems RT-PCR  (Applied Biosystems Viia 7) 
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Two-stage skin carcinogenesis 
Six to nine week old mice were used for these experiments. The dorsal skin of each 
mouse was shaved 48 hr before treatment. Mice were initiated with a single application 
of 25 nmol of DMBA. 2 weeks after initiation BK5.Stat3C transgenic and control mice 
received twice weekly applications of TPA (3.4 nmol or 6.8 nmol) until the experiment 
was terminated. Both DMBA and TPA were topically applied in 0.2 ml acetone. The 
number and incidence of skin tumors was determined weekly. Mann-Whitney U and Χ2  
tests were used to quantify statistical significance. 
  
Reagents and Antibodies  
Trypsin-EDTA (GIBCO), Dispase (GIBCO), Collagenase (GIBCO), Biotin-CD34 
(eBiosciences), α6-integrin-PE (BD), Streptavidin-APC (Invitrogen), Sca-1 (BD), Myc 
(Santa Cruz/MACS), Cyclin D1 (Cell Signaling Technology), β- catenin (Cell Signaling 
Technology), active β-catenin (SIGMA), Lgr6 (Santa Cruz), Lrig-1 (R&D), Keratin-15 
(Neomarkers), CD34 (BD). 
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Table 1. List of Antibodies 
Antibody Vendor Catalog # 
CD34-Biotin eBiosciences 13-0341-81 
Streptavidin-APC Invitrogen SA1005 
Sca-1 FITC BD 557405 
CD34-PE BD 551387 
Lgr6 Santa Cruz 99123 
Keratin-15 Neomarkers MS-1068-P0 
Keratin-1 Covance PRB-165P 
Keratin-10 Covance MMS-159S 
Loricrin Covance PRB-145P 
Involucrin Covance PRB-140C 
alpha-6 integrin 
(Flow) BD 561894 
alpha-6 integrin (IF) Santa Cruz sc-10730 
beta-catenin Cell Signaling Technology 9562 
active beta-catenin SIGMA C 7207 
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qPCR   
Gene Primer Forward Primer Reverse 
CD34 TCTTGGGCACCACTGGTTATTTCC AAGGTTCCAGCTCCAGCCTTTC 
Keratin-15 AGTCCAGATCGGGACTACAGCCATTAC 
GTTCTTCTTCAGGTAAGCCAGCTC
C 
Lgr-6 CTCAACAACCTTCCTGCCCTACAAG 
GAATGCTGACCTTCCCACAAACTG
GA 
MTS24 ATCCCAAAGCCAGTCGGTCTTC GTTGAGGCTGAGGGTTGTACTTG 
Lrig-1 ATGCTGCAGGCCTTTGTGACAG CTGGGTGATGATCTGTGGCTTTG 
Sca-1 AGGCAGCAGTTATTGTGGATTCTC TTAGGAGGGCAGATGGGTAAGC 
GAPDH TGTTCCAGAGACGGCCGCATCTTC 
ATTCTCGGCCTTGACTGTGCCGTT
G 
Keratin-1 GACACCACAACCCGGACCCAAAACTTAG 
ATACTGGGCCTTGACTTCCGAGAT
GATG 
Keratin-10 GGAGGGTAAAATCAAGGAGTGGTA TCAATCTGCAGCAGCACGTT 
Loricrin TCACTCATCTTCCCTGGTGCTT GTCTTTCCACAACCCACAGGA 
Involucrin GTCCGGTTCTCCAATTCGTGTTT GCAATTGGAAGAGAAGCAGCATCAG 
Keratin-5 AACATTTTGGGGTCTGGGTCAC GGCCCACAGAGACTGCTTCTTT 
Keratin-14 CGCCGCCCCTGGTGTGG ATCTGGCGGTTGGTGGAGGTCA 
Twist AAGATGGCAAGCTGAGCTATGTG 
TTATCCAGCTCCAGAGTCTCTAGA
C 
Snail ACGACCTGTGGAAAGGCCTTCTCTAG 
TGGTGCTTGTGGAGCAAGGACATG
C 
Slug AGCGAACTGGACACACACACAG GCCTTTCTCCTCTTACTGGATACTCCT 
Vimentin ATGTTGACAATGCTTCTCTGGCACGTC TTGGACTTGTACCATTCCTCGGC 
E-cadherin AGGGAGCTGTCTACCAAAGTG CTGGGAAACATGAGCAGCTCTGGGTT 
N-cadherin ACAGCGCAGTCTTACCGAAGGATGTG TCTGCAGTGAGAGGGAAGCTTC 
Fibronecti
n ACACTTATGAGCGCCCTAAAG TATAGGTTTGCAGGTCCATTCCCC 
Myc TGGATTTCCTTTGGGCGTTGGAAACC TCGCTCTGCTGTTGCTGGTGATAG 
Bcl-xl ATGCAGGTATTGGTGAGTCGGATTG 
GTTCCCGTAGAGATCCACAAAAGT
GT 
Stat3 AGCACAACCTTCGAAGAATCAAGCAG GGAGGTTCTCCACCACCTTCATT 
CyclinD1 AGTGCGTGCAGAAGGAGATTGTGC AGGAAGCGGTCCAGGTAGTTC 
Table 2. List of 
Primers 
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ChIP   
Sca-1 P1 CCCCAACTTGGAAAAGCATA CGTGAAAGACACGCTTTGAA 
Sca-1 P2 CTCGTGTGCAGTTTGCGTAT TGACACCAGAACCAAATCCA 
Sca-1 P3 GGAAAATCCCTGCTGTTTCA ATACGCAAACTGCACACGAG 
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Chapter 4 
1. K15.Cre X Stat3fl/fl mouse model  
Keratin-15 has been reported to be specifically active in the bulge region of the 
murine hair follicle. Morris et al., developed the Krt115EGFP transgenic mouse model, 
which facilitated isolation of bulge region cells from mice. These cells were shown to 
have a much greater proliferative potential when compared to the non-bulge 
keratinocytes and these cells also effectively reconstituted all epithelial cell types by the 
skin reconstitution assay. In addition, Morris et al., also generated the Krt115CrePR1 
mice. Cre PR1 is a fusion protein that comprises Cre recombinase and a truncated form 
of the progesterone receptor that binds to the progesterone antagonist RU486 but not to 
the endogenous progesterone. In these mice Cre recombinase remains inactive until 
the mice are treated with RU486. On RU486 treatment CrePR1 enters the nucleus and 
allows a recombination event that enables deletion of the gene or gene fragment 
flanked by the lox P sites (6). 
The K15.Cre PR1 mice were originally on a B6SJL/F1 genetic background and were 
crossed to the FVB/N genetic background for 10 generations in our lab, before any 
studies were performed. These mice were crossed to the Stat3fl/fl mice to generate mice 
hemizygous for K15.CrePR1 transgene and subsequently homozygous for Stat3 floxed 
alleles. Using this model, Stat3 was specifically disrupted in the bulge region KSCs 
using an inducible system. This system enabled the study of the role of KSCs in specific 
stages of skin tumorigenesis namely initiation, promotion and progression. 
 
2. Tumor phenotype 
The effect of Stat3 deletion specifically in the bulge region of the mouse hair 
follicle was examined using a bulge region specific knockout mouse model, 
K15.CrePR1 X Stat3fl/fl mouse. The effect of Stat3 deficiency on bulge region 
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keratinocyte stem cells was examined by subjecting these mice to DMBA-TPA induced 
two-stage skin carcinogenesis regimen. To induce the effect of Cre recombinase only 
during the initiation phase of skin tumorigenesis, K15.CrePR1 X Stat3fl/fl  and control 
mice were treated with 2mg/mouse RU486 once daily for 5 days prior to initiation with 
the carcinogen, DMBA. These mice were subsequently treated with 6.8 nmol TPA, 5 
weeks after the DMBA treatment. Stat3 deletion led to a significant reduction in tumor 
incidence. Twenty-two weeks after tumor promotion, there was a 70% reduction in the 
papilloma development in the knockout group compared to the control group. Western 
blot analysis of the skin tumors obtained from this study showed that the tumors from 
both knockout as well as the control group expressed Stat3 and phospho Stat3 which 
suggested that Stat3 was required for tumor development. The presence of Stat3 in the 
skin tumors from the knockout mice also suggested that Stat3 deletion was not 
complete in this mouse model. To further confirm that Stat3 deletion was not complete, 
total hair follicle cells were isolated by previously established protocols and fixed on a 
slide by cytospin. These cells were immunostained for K15 and Stat3 in the knockout 
and the control groups. Although RU486 treatment led to decreased Stat3 expression in 
the K15 expressing cells but not all the K15 expressing cells showed the absence of 
Stat3 (see Figure 6). These data further confirm that Stat3 deletion was only partial in 
K15 expressing keratinocytes. It may also suggest that populations other than the K15 
expressing populations may be contributing to tumor development by the two-stage skin 
carcinogenesis protocol (78) 
 
3. Stem cell phenotype 
To further understand the role of KSCs during the initiation phase  of skin tumor 
development in this mouse model, bulge region KSCs were analyzed by FACS 
analysis. For these studies, mice were treated with DMBA and bulge region KSCs were 
isolated 24hr after DMBA treatment. KSCs were analyzed for the expression of 
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hematopoietic stem cell marker, CD34 and α6-integrin positive cells. There was a 
reduction in the percentage of bulge region KSCs that were positive for CD34 and α6-
integrin in the knockout mice compared to the control mice 24 hr after DMBA treatment 
(see Figure 7). In addition, DMBA treatment led to a significant increase in the number 
of apoptotic keratinocytes in the bulge region of the knockout mice. These studies were 
done by immunohistochemistry followed by microscopic analyses of caspase-3 positive 
cells specifically in the K15 compartment (see Figure 8).  
      These data suggest that bulge region KSCs play an important role during the 
initiation step of skin tumor development by the two-stage chemical carcinogenesis 
protocol. Since Stat3 is known to affect both survival and proliferation of stem cells, 
absence of Stat3 led to increased apoptosis of bulge region KSCs ultimately leading to 
reduced number of putative carcinogen target cells for skin tumor development in this 
mouse model of skin carcinogenesis (78).  
Preliminary short-term studies showed that Stat3 deletion also played important roles 
during the tumor promotion phase of skin carcinogenesis. Studies are underway to 
examine the effect of Stat3 deletion during tumor promotion by specific deletion of Stat3 
only during tumor promotion using this inducible mouse model (K15.CrePR1 X Stat3fl/fl) 
that allows stage specific disruption of Stat3 (Kim DJ and Digiovanni J unpublished 
studies). 
	   37	  
  
Figure 6: Immunocytochemistry analysis of hair follicle cells after cytospin.  Total 
hair follicle cells were isolated by previously established protocols. The cells were fixed 
on the slide using cytospin. Cells from WT and KO were stained for K15 and Stat3 and 
observed microscopically. 
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Ref: (78) 
Figure 7: Deletion of Stat3 in the K15 expressing population led to decreased 
putative carcinogen target cells.  K15. Cre PR1 X Stat3fl/fl  mice and control mice 
were treated with RU486 (2 mg/0.2 ml acetone) for 5 days and subsequently with 
DMBA and sacrificed 24hr. later. (A). Contour plots showing the number of CD34/α6-
integrin positive cells in the knockout and control mice with and without DMBA. (B&C). 
Quantitation of percentage of CD34/α6-integrin positive cells analyzed by FACS 
analysis after 100 nmol and 1000 nmol DMBA treatment respectively.  
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Ref: (78) 
 
Figure 8:  Deletion of Stat3 in the bulge region of the hair follicles led to 
increased apoptosis. (A&B). Quantitation of IHC showing caspase-3 positive cells 
in the IFE and hair follicles of Stat3 KO mice. (C). IHC showing caspase-3 positive 
cells in the hair follicle of K15.CrePR1 X Stat3fl/fl mice.  
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Chapter 5 
1. K5.Cre X Stat3fl/fl mouse model  
K5.Cre transgenic mice and Stat3fl/fl mice were originally on 129/sv X C57BL/6 
genetic background and were backcrossed to a FVB/N congenic background for at 
least 5 generations. FVB/N is a sensitive genetic background for two-stage 
carcinogenesis experiments (79) (80). K5.Cre X Stat3fl/fl mice were generated by a 
bigenic cross between K5.Cre transgenic mice and Stat3fl/fl mice to ultimately 
generate mice that are hemizygous for the K5.Cre transgene and subsequently 
homozygous for the Stat3 floxed allele. These mice lead to Stat3 deletion in the K5 
compartment of the skin, which includes the epidermal basal cells, as well as the 
ORS of the hair follicle. Under normal conditions these mice do not exhibit any 
dramatic differences in their skin or hair phenotype when compared to age matched 
littermate control mice. 
 
2. Stem cell phenotype  
As described earlier stem/progenitor cells in the mouse hair follicles can be 
analyzed using a number of techniques including qPCR, flow cytometry and IHC. 
The bulge region stem cells were analyzed by LRC analysis and there was no 
statistically significant difference in the number of BrdU positive, LRCs in the KO 
mice as compared to the littermate control mice (see Figures 9A and 9B). There 
also was no difference in the expression of K15 in the Stat3 KO mice compared to 
the wild- type (WT) controls as observed by IHC (see Figure 9C). Hair follicle 
stem/progenitor cells were also analyzed by qPCR and no significant differences 
were observed in the levels of bulge region stem cell markers (see Figure 10). 
These data further support the observations that were shown in the K15.CrePR1 X 
Stat3fl/fl mouse model where no significant differences in the bulge region stem cell 
number was observed in the absence of TPA treatment (78). 
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Figure 9. Stat3 deletion in the K5 compartment of the skin does not affect the hair 
follicle bulge region stem cells. (A) 10 day old pups were given BrdU i.p. every 12 
hrs. for 2 days. Skins from K5.Cre+/- x Stat3fl/fl KO mice and control (K5.Cre -/- x 
Stat3fl/fl) mice were harvested after 70 days, fixed in formalin and embedded in paraffin. 
Sections were immunostained for BrdU. (B). LRCs were quantified by counting the 
average number of BrdU positive cells/50 follicles. (C) Skins from K5.Cre+/- x Stat3fl/fl 
KO mice and control mice were fixed in formalin and embedded in paraffin. Sections 
were immunostained for K15. 
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3. Differentiation phenotype 
Although Stat3 activation has been shown to maintain cells in an 
undifferentiated state, Stat3 has also been shown to be associated with 
differentiation in specific cell types (52) (54) (51) (53). As shown in Figure 10A and 
10B, deletion of Stat3 in the basal layer of mouse epidermis, including the bulge 
region of the hair follicle (using BK5.Cre+/- x Stat3fl/fl mice) led to an increase in the 
expression of classical epidermal keratinocyte differentiation markers. In this regard, 
there was an increase in Keratin1 and Loricrin in the IFE as shown by 
immunofluorescence staining of skin sections. K10 and Involucrin showed a similar 
pattern of altered expression (data not shown). Twenty-four hours following topical 
treatment with TPA (6.8nmol) Stat3 deficient mice had a much greater increase in 
the expression of these same differentiation markers (i.e., K1, K10, Loricrin and 
Involucrin) compared to similarly treated NTg mice. In contrast, no significant 
difference in mRNA levels was observed for the basal keratins, K5 and K14. These 
data suggest that deletion of Stat3 in the K5 compartment of the mouse epidermis 
results in altered differentiation in the IFE with less dramatic effects on the hair 
follicle stem/progenitor populations. 
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Figure 10. Deletion of Stat3 in K5.Cre+/- x Stat3fl/fl mice leads to differentiation of 
keratinocytes.  Skins from K5.Cre+/- x Stat3fl/fl  KO and control (K5Cre -/- x Stat3fl/fl ) mice 
were fixed in formalin and embedded in paraffin. Sections were immunostained for K15 
and K1 (A) and K15 and Loricrin (B) and examined microscopically. RNA from 
keratinocytes of K5.Cre+/- x Stat3fl/fl mice and control mice were analyzed for epidermal 
differentiation and stem/progenitor cell markers (C&D) 
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Chapter 6 
 
1. K5.Stat3C mouse model 
 
Constitutively active Stat3 
DNA bound Stat dimers interact with one another at their SH2 domains. The 
phosphor tyrosine residues on one monomer of Stat1 (residue 701) and Stat3 (residue 
705) bind to the SH2 domain on the other monomer of Stat1 (R602 and Stat3 (R608). 
This reciprocal interaction completes the homo or heterodimerization of Stat1 and Stat3 
proteins. Substituting residues A661 and N663 for cysteine residues allows for cysteine-
cysteine sulfhydryl bonds between the monomers (Stat3), which allows for the formation 
of a dimerized Stat3 molecule without the Y705, called Stat3C. Stat3C molecule was 
made by site directed mutagenesis (see Figure 11). In addition a flag tag was added for 
tracking the molecule in cells and tissues (again see Figure 11). The ability of Stat3C to 
activate transcription constitutively was tested using cells expressing WT Stat3 or 
Stat3C by transient transfections with reporter gene tagged to a Stat3 DNA binding 
sequence. Stat3C expression was found to lead to transcriptional activation in these 
experiments using 293T, 3Y1, NIH3T3 and HepG2 cells where as the WT Stat3 
expressing cells did not show any transcriptional activation without tyrosine 
phosphorylation. However, induction with IL-6, transcriptional activation by WT Stat3 
became evident as well as a further increase in the Stat3C dependent transcription was 
also seen. These data suggested that Stat3C expression leads to its constitutive 
activation followed by transcription of its targets (81). Studies from our lab and others 
showed that Stat3C may be involved in increased levels of mRNA expression of genes 
like cyclin D1, Bcl-xl and c-myc which are some of the endogenous genes regulated by 
Stat3 (71). 
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Figure 11: Representation of Stat3C structure. (A). Representation of Stat3 domains 
(B) Representation of BK5.Stat3C construct (C) Representation of the Stat3C dimer
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2. Stem cell phenotype 
 
BK5.Stat3C mice have reduced number of bulge region KSCs 
The long term label retaining cells (LRC) population in the bulge region of 
BK5.Stat3C transgenic (Tg) was compared to that of non-transgenic (NTg) mice. For 
these experiments, 10-day-old pups were pulse labeled with BrdU (given i.p. using the 
protocol described in the Materials and Methods) and then chased for 70 days. As 
shown in Figure 12A, there was a significant decrease in the number of LRCs in the hair 
follicles of BK5.Stat3C Tg mice compared to NTg mice. For these experiments, the 
LRCs were quantitated by two independent methods. First, the percent hair follicles that 
contained BrdU positive cells were counted. Second, the average number of BrdU 
positive cells/ 50 hair follicles in both groups of mice was counted. Both methods 
revealed a statistically significant decrease in the number of LRCs in the Tg mice when 
compared to the NTg mice (see quantitation in Figure 12B).  
To understand if expression of a constitutively active form of Stat3 in the hair 
follicles led to an imbalance in the progenitor/stem cell populations, total hair follicle 
cells were isolated from both groups and used for clonal assays by plating on mitomycin 
C treated NIH3T3 cells. Closely packed holoclones and more disperse 
paraclones/meroclones in both groups were counted (see Figure 12C). Hair follicle cells 
from BK5.Stat3C Tg mice had decreased number of holoclones and increased number 
of paraclones/meroclones compared to the hair follicle cells from NTg mice (see 
quantitation in Figure 12D). Taken together these data suggested that expression of a 
constitutively active form of Stat3 in the K5 compartment led to an increase in the TA 
cell populations and a reduction of bulge region KSCs. 
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Figure 12. Constitutive expression of Stat3C leads to decreased LRCs and 
holoclones. A. 10 day old pups were given BrdU i.p. every 12 hrs. for 2 days. Skins 
from BK5.Stat3C Tg and littermates (NTg) were harvested after 70 days, fixed in 
formalin and embedded in paraffin.  Sections were immunostained for BrdU. B. LRCs 
were quantified by (i) counting the percent hair follicles that show BrdU positive cells 
and (ii) counting the average number of BrdU positive cells/50 follicles. C. Hair follicle 
cells were isolated from BK5.Stat3C Tg mice and littermates (NTg) and plated on 
mitomycin C treated NIH3T3 cells and cultured for 4 weeks. D. Clones were quantified 
by counting holoclones and mero/paraclones. * p < 0.05 
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Expression of hair follicle stem/progenitor cell markers in the hair follicles 
There was decreased expression of K15 in the hair follicle bulge region of Tg 
mice as compared to the NTg (see Figure 13). Moreover, the structure of the bulge 
region in the Tg mice was less well defined (see again Figure 13) although the hair 
follicles in BK5.Stat3C Tg mice appeared to undergo normal hair cycle stages of 
anagen, catagen and telogen (see Figure 14). The expression of K15 during both the 
anagen as well as the catagen/telogen stages of the hair cycle was also examined and 
found to be decreased during both of these hair cycle phases (Figure 15). Bulge region 
KSCs can also be analyzed by expression of CD34 and α6-integrin (5). Therefore, the 
number of CD34 and α6-integrin double positive cells in the hair follicles of BK5.Stat3C 
Tg and NTg mice were analyzed by flow cytometry analysis. A decreased number of 
double positive cells was observed in the hair follicles of BK5.Stat3C Tg mice compared 
to the NTg mice (Figure 16A). In addition, there was an increase in the number of Sca-1 
positive progenitor or TA cell population in the Tg mice as compared to NTg mice by 
flow cytometry analysis (Figure 16B).  These data are representative of multiple 
independent experiments. 
Immunohistochemical and qPCR analyses were used to further study the 
expression of various hair follicle stem/progenitor markers. As shown in the Figure 16C, 
there was a decrease in staining for both CD34 and K15 in the bulge region of Tg as 
compared to the NTg mice. These data are consistent with the data presented in Figure 
16A and Figure 13. Notably, there was an increase in staining for Sca-1 in the hair 
follicles of Tg mice consistent with the data shown in Figure 16B. Further analyses 
revealed an increase in the expression levels of Lrig-1 and Lgr6 (Figure 16C and Figure 
17, respectively). These results were further confirmed by qPCR analyses which 
showed a decrease in the mRNA levels of CD34, K15 and MTS24, which represent 
more stem like cells and increased levels of mRNA for the progenitor cell markers 
including Lgr-6, Lrig-1 and Sca-1 (Figure 16D). In addition, expression of another well-
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known stem cell marker p63 was analyzed by immunofluorescence and no significant 
difference in either the number of cells expressing p63 or level of p63 expression was 
seen between Tg and NTg mice (Figure 17). 
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Figure 13. Expression of Stat3 leads to altered bulge region morphology. Skins 
from K5.Stat3C Tg and NTg mice were fixed in formalin and embedded in paraffin. 
Sections were immunostained for K15 to study the structure of the bulge region. 
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Figure 14. Stat3C expression does not alter the hair cycle. Skins from BK5.Stat3C 
Tg and NTg mice were fixed in formalin and embedded in paraffin. Sections were 
immunostained with H & E. 
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Figure 15: Keratin-15 expression in the anagen and catagen/telogen phases of 
hair cycle of BK5.Stat3C and control mice. Dorsal skins of BK5.Stat3C transgenic 
and non-transgenic mice were fixed in formalin and embedded in paraffin. Skin sections 
were immunostained for Keratin 15 and observed microscopically.
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Figure 16.  Expression of Stat3C causes an increase in the transit amplifying (TA) 
population at the expense of bulge stem cells. A. Total hair follicle cells were 
subjected to flow cytometry analysis after staining for CD34 and α6-integrin. B. Flow 
cytometry analysis of hair follicle cells for expression of Sca-1 C. Skins from 
BK5.Stat3C Tg mice and littermates (NTg) were fixed in formalin and embedded in 
paraffin or frozen in OCT. Sections were stained for CD34, Keratin-15, Lrig-1 and Sca-1 
and examined microscopically. D. Epidermal keratinocytes were harvested from 
BK5.Stat3C Tg mice and littermates (NTg), RNA was isolated and lineage markers 
analyzed by qPCR analysis. *p= 0.0003, **p= 0.00051 
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Figure 17. Stem/progenitor marker expression in the hair follicle of BK5.Stat3C 
mice. (A) Skins from BK5.Stat3C Tg and NTg mice were fixed in formalin and 
embedded in paraffin. Sections were immunostained for K15 and Lgr-6. (B) Skins from 
BK5.Stat3C Tg and NTg mice were fixed in formalin and embedded in paraffin. Sections 
were immunostained for p63. 
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Stat3 directly regulates Sca-1 gene expression in keratinocytes 
Earlier reports suggested that the Sca-1 promoter has gamma-interferon 
activating sequences (GAS), which may be putative Stat3 binding sites (82). An SCC 
cell line (JWF2) was used to examine the induction of Sca-1 mRNA by various inducers 
and inhibitors which are known to modulate Stat3 signaling and function. JWF2 cells 
were treated with IL-6 and EGF and harvested 3 hr later. Induction of Stat3 signaling 
was confirmed by analyzing the levels of Cyclin D1 mRNA, a known Stat3 target gene. 
Cyclin D1 levels were elevated 3 hr after treatment with both EGF and IL-6 (see Figure 
18).  STA-21, which is an established Stat3 inhibitor (83), reduced both EGF and IL-6 
induced cyclin D1 mRNA levels.  As shown in Figure 19A, the level of Sca-1 mRNA was 
also increased following treatment with both EGF and IL-6 while Sca-1 mRNA levels 
induced by these ligands were again reduced when the cells were pretreated with STA-
21 for 1 hr. A similar decrease was seen in the mRNA expression of Sca-1 when dorsal 
skins of BK5.Stat3C mice were harvested after treatment with STA-21 (see Figure 19B). 
The Sca-1 promoter was analyzed for Stat3 binding sites and found to have 
TTNNNNNAA generic sequences that could be Stat3 binding sites. ChIP analysis was 
performed to examine if Stat3 is involved in direct regulation of Sca-1. As shown in 
Figure 19C and 19D, the Sca-1 signal relative to input was amplified in the Stat3C Tg 
mice as compared to the NTg controls. The binding of Sca-1 was specifically mediated 
by Stat3, which was confirmed by using β-catenin as the negative control for 
immunoprecipitation. These data suggest that Stat3 regulates the expression of Sca-1 
by direct binding to its promoter region. 
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Figure 18. CyclinD1 mRNA expression after EGF or IL-6 and the 
effect of STA-21 treatments. JWF2 cells were treated with EGF, IL-6 for 3 hr. For 
treatments that include STA21, cells were pretreated with STA21 for 1 hr and then 
treated with EGF or IL-6. RNA isolation and cDNA preparation was done to analyze 
mRNA levels of cyclin D1. 
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Figure 19. Sca-1 is a direct target of Stat3. (A) JWF2 cells were treated with EGF or 
IL-6 for 3 hr.  For treatments that include STA-21, cells were pretreated with STA-21 for 
1 hr and then treated with EGF or IL-6. RNA isolation and cDNA preparation were done 
to analyze mRNA levels of Sca-1. (B) BK5.Stat3C Tg and NTg mice were treated with 
20 µM STA-21 topically twice every week for 2 weeks and Sca-1 gene expression levels 
with and without STA-21 treatment was analyzed using qPCR. (C) Epidermal scrapings 
from BK5.Stat3C Tg mice and littermates (NTg) were used to perform ChIP analysis. β-
catenin and Stat3 were used for immunoprecipitation and the DNA was amplified using 
Sca-1 primers. Input controls were used for each sample and IgG was used as a 
negative control. (D) Graphs representing quantification of Sca-1 positive bands 
normalized to input. 
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3. Differentiation phenotype 
Since expression of Stat3C in the basal layer led to increased expression of hair 
follicle progenitor cell markers and decreased number of bulge region KSCs, markers of 
keratinocyte differentiation were analyzed to examine if Stat3C overexpression leads to 
an overall increase in differentiation. As shown in Figure 20, there were no significant 
differences in the expression pattern or levels of classical differentiation markers 
including Keratin1, Keratin 10, Loricrin and Involucrin in the IFE as analyzed by 
immunofluorescence. These data suggested that Stat3C expression primarily affected 
the migration and/or maturation of hair follicle stem/progenitor cells. 
As shown earlier there was increased mRNA expression of progenitor or transit 
amplifying cells in the BK5.Stat3C mice. An increase in the number of certain TA 
populations e.g. Lrig-1 and Sca-1 was also seen. These data may suggest 
differentiation of stem cell populations into progenitor or TA cells. However, these 
observations could also have been due to the migration of the bulge region cells into TA 
cell populations like Sca-1, which we have found to be one of the genes directly 
regulated by Stat3. Lineage tracing studies need to be done to further understand the 
behavior of the hair follicle bulge resident keratinocyte stem cells. 
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Figure 20. Stat3C expression does not cause an increase in the expression of 
differentiation markers in the epidermis. Skins from BK5.Stat3C Tg mice and NTg 
littermates were fixed in formalin and embedded in paraffin. Sections were 
immunostained for Keratin-1, Keratin-10, Loricrin and Involucrin and examined 
microscopically. 
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4. EMT phenotype 
 
Constitutive activation of Stat3 leads to increased β-catenin and c-myc 
expression and reduced α6-integrin expression in the bulge region of Tg mice  
Both total as well as nuclear β-catenin expression levels were examined in the 
hair follicles of BK5.Stat3C Tg and compared to age-matched NTg mice. As shown in 
Figure 21A, hair follicles from NTg mice had a very well defined bulge region marked by 
K15 expression but little or no expression of β-catenin in the bulge region. On the other 
hand, in Tg mice β-catenin expression was observed throughout the ORS (again see 
Fig 21A). Nuclear β-catenin levels were also evaluated and increased nuclear 
localization of β-catenin was observed in the hair follicles of Tg mice (see Figure 21B). 
In addition, hair follicles of Tg mice had reduced expression of α6-integrin as analyzed 
by both flow cytometry and immunofluorescence analyses (Figure 21C). Thus, 
constitutive activation of Stat3 in the K5 compartment led to altered expression of both 
β-catenin and α6 integrin that may have contributed to the changes seen in hair follicle 
morphology and stem/progenitor cell populations. Myc expression was also found to be 
elevated in BK5.Stat3C mice as observed by immunofluorescence and flow cytometry 
analysis (see Figure 22A and 22B). We have previously shown that Stat3 directly 
regulates Myc expression in the epidermis (71). Earlier studies have shown that Myc is 
a direct transcriptional target of both Stat3 (84) and β-catenin (85) both of which are 
elevated in BK5.Stat3C mice (see again Figure 21). These results suggest that Myc 
may contribute to the effects seen on the stem/progenitor populations in these mice. 
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Figure 21. Expression of Stat3C leads to increased expression of β-catenin and 
decreased expression of α6-integrin in the hair follicle. Skins from Tg mice and 
NTg littermates were fixed in formalin and embedded in paraffin. Sections were co-
immunostained for Keratin-15 and total β-catenin (A) and co-immunostained for Keratin-
15 and nuclear β-catenin (B) and examined microscopically (Green- Keratin-15, Red- β-
catenin, Blue-DAPI). (C) (i) Flow cytometry analysis of α6-integrin positive cells in 
BK5.Stat3C Tg and NTg mice. p=0.006. (ii) Immunofluorescence analysis to analyze 
the expression of α6-integrin in the hair follicles of BK5.Stat3C Tg and NTg mice. 
	   62	  
 
Figure 22. c-Myc Expression analysis BK5.Stat3C transgenic mice. (A) Skins from 
BK5.Stat3C Tg and NTg mice were fixed in formalin and embedded in paraffin. Sections 
were co-immunostained with K15 and c-Myc. (B) FACS analysis to analyze the number 
of Myc positive cells in BK5.Stat3C mice compared to control mice. 
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Stat3C expression in the K5 compartment induces epithelial to mesenchymal 
transition (EMT)  
To further understand the mechanism(s) underlying the decrease in CD34 
positive bulge region KSCs, markers associated with EMT were analyzed at the mRNA 
level by qPCR. There was a marked increase in the mRNA levels of twist, snail, slug, 
fibronectin, vimentin and α-smooth muscle actin (63) and a decrease in the level of e-
cadherin (Figure 23). In an earlier study, we observed increased expression of Twist, a 
Stat3 target gene in skin tumors induced by a two-stage carcinogenesis protocol in the 
BK5.Stat3C mice. Thus, upregulation of EMT related genes may contribute to the 
observed decrease in the number of bulge region KSCs and increased progenitor 
populations seen in BK5.Stat3C Tg mice. 
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Figure 23. Expression of Stat3C in the K5 compartment induced epithelial-to-
mesenchymal transition.  Epidermal keratinocytes were harvested from BK5.Stat3C 
Tg and NTg mice, RNA was isolated and qPCR analysis was done to analyze EMT 
markers. 
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Chapter 7 
BK5.Stat3C Mouse Model and Cancer Stem Cell 
1. Tumor phenotype 
 
BK5.Stat3C mice do not develop spontaneous tumors. In two-stage chemical 
carcinogenesis experiments, BK5.Stat3C mice developed skin tumors with shortened 
latency compared to non-transgenic littermates. This occurs due to an enhanced 
proliferative response of BK5.Stat3C keratinocytes to TPA (84). Remarkably, 100% of 
skin tumors from BK5.Stat3C transgenic mice bypassed the premalignant stage and 
initially developed as carcinoma in situ (see Figure 24). Histological and 
immunohistochemical analysis revealed that these tumors are highly vascularized and 
poorly differentiated and invasion into surrounding dermal/mesenchymal tissue was 
observed at a very early stage. In addition, expression of K10, filaggrin and E-cadherin 
was completely lost in skin tumors from K5.Stat3C transgenic mice by 20 weeks.  
In addition to the two-stage chemical carcinogenesis, BK5.Stat3C mice were found to 
be highly sensitive to a UVB carcinogenesis protocol as well. Stat3 could impact the 
survival and proliferation of keratinocytes which led to increased incidence as well as 
increased multiplicity of skin tumors in the BK5.Stat3C mice when subjected to the UVB 
skin carcinogenesis protocol (70). Constitutive expression of Stat3C increased the 
survival of keratinocytes including those in the bulge region of the hair follicle by 
protecting the cells from UVB induced apoptosis thus playing a role in increased 
survival of keratinocytes. Constitutive expression of Stat3C also led to increased 
proliferation and hyperplasia in the epidermis in response to UVB treatment. Taken 
together, these studies suggest that Stat3 plays important roles in skin tumor 
development by both two-stage chemical as well as UVB-induced skin carcinogenesis 
protocol. 
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Figure 24: Skin tumor response in BK5.Stat3C mice subjected to two-stage 
chemical carcinogenesis protocol.  Groups of mice were initiated with 25 nmol 
DMBA and promoted with 3.4nmol TPA (A). Skin tumors in control and BK5.Stat3C 
transgenic mice subjected to the two-stage skin carcinogenesis regimen. (B). Tumor 
incidence and tumor multiplicity (C). Representative H&E stained skin tumors after 12 
weeks of TPA treatment. 
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2. Stem Cell phenotype of BK5.Stat3C tumors 
Skin tumors that develop in the BK5.Stat3C mice completely bypass the 
premalignant stage, papilloma, and directly develop as carcinomas in situ. These 
tumors are highly vascularized and invasive. The tumors rapidly progress to squamous 
cell carcinoma and invade the basement membrane. To further analyze the role of stem 
cells in the tumors that developed in BK5.Stat3C mice, the tumors generated by the 
two-stage chemical carcinogenesis regimen were analyzed by immunohistochemistry. 
Various markers were examined with an initial focus on the bulge region keratinocyte 
stem cell marker, CD34 and TA cell marker that was found to be expressed in the 
infundibulum area of the mouse hair follicle, Sca-1. Interestingly, it was observed that 
there was increased expression of CD34 in the papillomas derived from the non-
transgenic mice. There were very few Sca-1 positive cells seen in these papillomas as 
shown in Figure 25. The SCCs from the non-transgenic mice showed both CD34 as 
well as Sca-1 positive cells. However, when the SCCs from the BK5.Stat3C mice were 
analyzed for the expression of CD34 and Sca-1 in serial sections, an increased 
expression of Sca-1 positive cells was observed in these tumors. Although the SCCs 
from control mice showed expression of both CD34 and Sca-1, these markers did not 
show a co-localized expression pattern, instead were found to be expressed in 
completely separate cellular compartments of the tumor. These data may suggest that 
either these two cell populations arise from two different cells of origin or that the Sca-1 
positive cells originate from the same precursor as the CD34 expressing cells but 
evolved into a population that has a completely different marker profile from its 
precursor.   
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Figure 25: Skin tumors from BK5.Stat3C transgenic mice show decreased 
CD34 and increased Sca-1 expression. Skin tumors from NTg and Tg mice were 
harvested after 21 weeks of TPA treatment. (A). OCT frozen papilloma serial 
sections from NTg were immunostained for CD34 and Sca-1 expression. (B). OCT 
frozen SCC serial sections from NTg were immunostained for CD34 and Sca-1 
expression. (C). OCT frozen SCC serial sections from BK5.Stat3C Tg were 
immunostained for CD34 and Sca-1 expression. 
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Earlier studies from our lab have shown that the skin tumors that develop in BK5.Stat3C 
mice are very aggressive and poorly differentiated. In addition, it was also observed that 
there was a loss of differentiation markers K10, filaggrin and down-regulation of E-
cadherin in these mice by week 20 of the two-stage skin carcinogenesis protocol (86). 
To further understand the role of stem/progenitor populations in the skin tumors of 
BK5.Stat3C Tg mice, early and late skin tumors were harvested from the Tg and control 
mice. Early tumors were harvested at week 12-14 and late tumors were harvested 
between weeks 22-24 of the DMBA-TPA protocol. These tumors were stained for 
stem/progenitor markers including CD34 and Sca-1 as well for keratins K1 and K5. As 
observed earlier, the SCCs obtained from the BK5.Stat3C mice showed decreased 
expression of epidermal differentiation marker K1 when compared to the papillomas 
obtained from the control mice, which showed K1 expression (see Figure 26 and Figure 
27). As seen earlier, there was increased expression of Sca-1 and decreased 
expression of CD34 in the skin tumors from Tg mice compared to the NTg mice. 
Notably, Sca-1 expression was more pronounced in the areas that had reduced K1 
expression or were poorly differentiated. Studies are underway with additional tumors to 
analyze the expression of CD34 vs. Sca-1 in the compartments of the tumor that 
express basal epidermal (K5) or epidermal differentiation (K1) markers. In addition, we 
are currently conducting experiments to study the expression profiles of various other 
stem/progenitor markers in these tumors. Preliminary quantitative RT-PCR studies 
indicate increased expression of progenitor markers vs. stem cell markers in the tumors 
obtained from BK5.Stat3C mice (see Figure 28) but additional tumors need to be 
analyzed for a definitive conclusion. 
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Figure 26: WT Papillomas show increased CD34 and differentiation marker 
expression. Formalin fixed or OCT frozen skin tumor samples from FVB mice under 
the two-stage skin carcinogenesis regimen were harvested and immunostained for 
stem/progenitor cell markers. They were also stained for analyzing the expression of K1 
(marks the differentiated layer) and K5 (marks the epidermal basal cells). 
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Figure 27: BK5.Stat3C SCCs show increased Sca-1 and loss of differentiation 
marker expression. Formalin fixed or OCT frozen skin tumor samples from 
BK5.Stat3C mice under the two-stage skin carcinogenesis regimen were harvested and 
immunostained for stem/progenitor cell markers. They were also stained for analyzing 
the expression of K1 (marks the differentiated layer) and K5 (marks the epidermal basal 
cells). 
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Figure 28: Advanced tumors from BK5.Stat3C mice showed increased levels of 
hair follicle progenitor cell markers. Skin tumors from WT papillomas, WT SCCs and 
BK5.Stat3C SCCs were obtained from mice subjected to the two-stage chemical 
carcinogenesis protocol. Tumors were homogenized and pooled for RNA isolation 
followed by cDNA preparation. Hair follicle stem and progenitor marker genes were 
analyzed using quantitative RT-PCR 
. 
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3.  Sca-1’s role in tumor development and tumor progression 
       Repression of Sca-1 showed reduced cell growth and tumorigenicity of 
mammary carcinoma cells. Loss of Sca-1 decreased the spheroid forming ability of this 
cell line. Engraftments of the Sca-1 knock down cell line into syngeneic mice failed to 
give rise to tumors as in the control mice. The few tumors that did develop had a much 
smaller size (23). This study concluded that Sca-1 inhibited TGF-β signaling and 
repression of Gdf10, which is a TGF-β ligand. Another study from the Glazer group 
reported that Sca-1 deficient mice showed a delayed onset of tumor development in 
medroxyprogesterone (MP) and 7,12 dimethylbenz(a)anthracene (DMBA) induced 
tumor model of mammary carcinogenesis. In this study, the mechanism underlying 
reduced tumor development in Sca-1 deficient mice was due to upregulation and 
activation of PPARγ (87).  High Sca-1 expression also correlated very strongly with 
Wnt1 expression in transgenic mouse models of mammary tumorigenesis (88). Xin L et 
al showed altered Akt signaling may result in initiation of prostate tumorigenesis and 
cancer progression correlated with an increase in Sca-1 positive cells (22). In addition 
to the prostate and breast tumors, Sca-1 upregulation is often observed in 
retinoblastoma (89). In humans Ly6 proteins like prostate stem cell antigen (PSCA) 
correlate with advanced tumor stages. The cells that expressed higher levels of Sca-1 
also showed upregulated expression of urokinase plasminogen activator (UPA), another 
Ly6 family protein which is also linked to tumor development and metastasis (90). Thus, 
Sca-1 in association with multiple signaling pathways including TGF-β, PPARγ, PI3K-
Akt and Wnt can alter tumor development.  
 In addition to its roles in tumor development, Sca-1 has also been reported to be 
involved in promoting cell migration by altering the cell’s adhesive interaction with a 
variety of ECM substrates. Studies from Batts et al suggest that Sca-1 may be involved 
in epithelial-ECM interactions however the underlying mechanism or the direct 
downstream effectors of this function have not been determined (91).  
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Chapter 8 - Discussion 
 
 
 In the present study, we have shown that Stat3 plays an important role in behavior 
of keratinocyte stem/progenitor cells that reside in the hair follicle. The expression of a 
constitutively active/dimerized form of Stat3 in the basal compartment of mouse 
epidermis and in the bulge region of the hair follicle led to a dramatic effect on the bulge 
region KSCs.  In this regard, BK5.Stat3C mice had reduced number of CD34/ α6-
integrin positive cells and reduced number of LRCs. Furthermore, total hair follicle cells 
from BK5.Stat3C mice grown on mitomycin-C treated fibroblasts showed reduced 
number of holoclones compared to those from NTg mice.  Although the BK5.Stat3C 
mice had a reduced number of bulge region KSCs, these mice had increased number of 
TA cell populations, especially the Sca-1 expressing cell population.  An increase in 
several other progenitor cell populations, including the Lgr-6 and Lrig-1 populations was 
also observed.  In addition to a decreased number of CD34/α6-integrin positive cells, 
there were decreases in the expression of K15 and MTS-24.  Further analyses revealed 
that Stat3C expression led to changes in expression of β-catenin, c-Myc, α6-integrin 
and EMT-related genes consistent with maturation and upward migration of bulge 
region KSCs.  Moreover skin tumors obtained by subjecting BK5.Stat3C mice to the 
two-stage skin carcinogenesis regimen completely bypassed the premalignant phase of 
skin tumorigenesis and developed as carcinoma in situ that rapidly progressed to 
squamous cell carcinoma. Initial analysis of these tumors had revealed a loss of 
differentiation markers, downregulation of E-cadherin and increased Twist expression 
(86). Detailed analysis of these tumors revealed increased expression of Sca-1 and 
decreased expression of CD34 in advanced SCCs compared to increased expression 
of CD34 and decreased expression of Sca-1 in early papillomas suggesting the role of 
multiple stem/progenitor populations in tumor development in this mouse model. In 
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contrast to these results with BK5.Stat3C mice, deletion of Stat3 in the basal layer 
(K5.Cre+/- x Stat3fl/fl mice) led primarily to changes in epidermal differentiation in the IFE 
and only marginal effects on stem/progenitor cell population in the hair follicle.  In 
addition, Stat3 deletion in the bulge region specific KSCs led to reduced tumor 
development. To further unveil the underlying mechanisms another mouse model 
K15Cre.PR1 X Stat3fl/fl was used. In these mice where Stat3 is specifically deleted from 
the bulge region KSCs, Stat3 disruption in the KSCs, the putative carcinogen targets led 
to decreased survival of these cells by inducing their apoptosis during the initiation 
phase of skin tumorigenesis. Overall, the current results demonstrate that Stat3 plays 
important roles in the migration and maturation of KSCs, KSC proliferation and survival 
and also affects keratinocyte differentiation. These effects may depend in part on the 
keratinocyte niche as well as the complement of genes altered by changes in Stat3 
activity.  
 
 An interesting result in our current study was the finding that expression of Stat3C 
led to a significant reduction in bulge region KSCs (as assessed by expression of CD34, 
α6-integrin and K15 as well as LRC analyses and holoclone assay).  Based on the 
current data, one possible explanation is that increased expression of specific Stat3 
regulated genes led to maturation and migration of these cells out of the bulge region 
niche. One of these Stat3 regulated genes appears to be Sca-1.  Recent evidence has 
indicated that Sca-1 is a target gene for Stat3 in the duct cells of the mouse 
submandibular gland (92, 82).  In the current study, we confirmed by ChIP analysis that 
Sca-1 is a direct target for Stat3 in mouse keratinocytes. Thus, increased expression of 
Sca-1 in bulge region KSCs may have facilitated movement upward toward the 
infundibulum leading to an increase in the number of cells in this compartment.  The 
increase seen in other progenitor markers/cell populations (Lrig-1 and Lrg6) that reside 
in the hair follicle between the CD34 positive and Sca-1 positive populations may be the 
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result of upward migration induced as a result of elevated Sca-1 expression.   
 In previous studies, it was reported that deregulated expression of Myc under the 
control of the K14 promoter led to alterations in stem cell maintenance and a 75% 
reduction in the number of stem cells in these K14.Myc2 mice (93). Additional studies 
also showed that transient activation of c-Myc in K14.MycERTM transgenic mice drove 
keratinocytes from the stem to the TA compartment (94). As shown in the 
supplementary Figure 22 increased expression of myc in the hair follicles of BK5.Stat3C 
mice in cooperation with elevated Sca-1 may have contributed to the migration of stem 
cells out of the bulge region of the hair follicles.  
It is known that β-catenin stabilization is essential for promoting the transition 
between stem cell quiescence and conversion to proliferating TA progeny (41). It is also 
known that ectopic expression of either stabilized β-catenin or a regulated form of β-
catenin induces cell migration in different cell types. Also, a critical threshold of β-
catenin signaling activated by cooperative mechanisms may be important during EMT 
and tumorigenesis (70). Studies have shown that β-catenin expression levels may be 
critical in both specifying cell fate decisions in stem cells and continued expression and 
stabilization of the protein may contribute to tumorigenesis (95, 96). In addition, α6-
integrin is known to provide adhesive interactions between epithelial cells and the 
basement membrane (97). In the current study, we analyzed the expression of both 
total β-catenin as well as active β-catenin in the nucleus of the hair follicle bulge cells in 
both the Tg as well as the NTg mice. We observed elevated levels of β-catenin protein 
in the bulge region of BK5.Stat3C Tg mice, which may have contributed to the 
increased migration of bulge region KSCs out of their niche. We also observed by both 
flow cytometry and immunofluorescence analysis that the Tg mice showed decreased 
expression of integrin (α6) in the bulge region, which may also have contributed to the 
migration of the KSCs out of the bulge region by decreasing the adhesive interactions 
between epithelial cells and the basement membrane. Thus, Stat3-induced changes in 
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β-catenin and α6-integrin expression together with elevated c-Myc and Sca-1 may have 
cooperated in facilitating movement of KSCs out of the bulge-region. Yang et al (98) 
also recently showed that elevated c-myc and β-catenin levels likely contributed to the 
depletion of bulge-region KSCs in Smad4 KO mice. 
 To better understand the mechanism(s) underlying the movement of stem cells 
into the progenitor populations, expression of EMT markers was also analyzed in the 
current study. As shown in Figure 23, qPCR analyses of epidermal RNA samples 
demonstrated increased mRNA levels for N-cadherin, Vimentin, Fibronectin and α-SMA 
as well as an increase in the expression of Twist, Snail and Slug. These data suggested 
that expression of Stat3C induced an EMT phenotype in the keratinocytes from the Tg 
mice. The reduced expression of E-cadherin (Figure 23) is also consistent with this 
hypothesis. In addition, earlier studies from our lab demonstrate that skin tumors from 
BK5.Stat3C mice had increased levels of Twist (86). Twist is a known target gene for 
Stat3 (99). Twist is known to regulate EMT by downregulating the expression of 
epithelial specific proteins, such as the E-cadherin and by upregulating the expression 
of mesenchymal markers such as N-cadherin, vimentin and αSMA (100, 101). These 
data suggest that constitutive expression of Stat3C in these mice may have induced 
EMT by directly upregulating Twist thereby modulating expression of several EMT 
related genes and further facilitating the migration of the cells out of the bulge-region 
niche. 
 As part of this study, we analyzed stem cells as well as epidermal differentiation 
markers in the K5.Cre+/- x Stat3fl/fl mouse model. Notably, deletion of Stat3 in the basal 
layer of the epidermis and the ORS of the hair follicle in these mice led to increased 
keratinocyte differentiation primarily in the IFE. In this regard, deletion of Stat3 in the K5 
compartment led to increased expression (assessed by both mRNA levels and 
immunofluorescence analyses) of K1, K10, Loricrin and Involucrin in the IFE. The 
increased expression of differentiation markers in the IFE was further enhanced 
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following treatment with TPA (Figure 7). Recently, we reported that STA-21 (a Stat3 
inhibitor) treatment altered keratinocyte morphology and increased the expression of 
Keratin1, Keratin 10, Loricrin and transglutaminase (102). Collectively, the current and 
previous data support the hypothesis that Stat3 may regulate keratinocyte 
differentiation. The mechanism whereby deletion of Stat3 leads to keratinocyte 
differentiation remains to be determined. However, a previous report showed that 
deletion of c-Myc induced keratinocyte stem cells to stop proliferating and to undergo 
terminal differentiation (103).  Myc is a known Stat3 target gene in keratinocytes (71) 
and reduced levels of c-Myc in the Stat3 knock-out mice may have partially contributed 
to the epidermal differentiation phenotype seen in these mice. 
 In contrast, deletion of Stat3 led to a dramatic inhibition of skin tumor initiation in a 
two-stage skin carcinogenesis assay. Absence of Stat3 led to decreased survival of 
DNA damaged KSCs located in the bulge region of the murine hair follicle. These 
studies provide direct evidence to the role of bulge region KSCs as primary carcinogen 
targets. Bulge region cells were found to be critical for tumor development in this mouse 
model of skin carcinogenesis, which supports the earlier studies that established the 
tumorigenic potential of CD34 positive bulge region cells. Although bulge region cells 
are known to be primary targets of carcinogenesis in the two-stage model, recent 
reports have suggested the involvement of other stem/progenitor populations in 
squamous papillomas and SCC development and progression (104). In addition, 
genomic profiling and hierarchical cluster analysis showed that more than one 
stem/progenitor cell populations that may or may not share a molecular signature may 
be involved in SCC formation (105). It is also interesting to note that in spite of 
decreased bulge region KSCs, the putative target cells for tumor formation in mouse 
skin (6) BK5.Stat3C mice were highly susceptible to both two-stage and UV skin 
carcinogenesis protocols (86, 78). In particular, skin tumors that develop in BK5.Stat3C 
mice undergoing two-stage chemical carcinogenesis progress rapidly to invasive SCC 
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(86). The current findings suggest that expression of Stat3C caused an increase in TA 
cell populations above the bulge region, which may be causally involved in the 
characteristic tumor response in BK5.Stat3C mice. Since the Sca-1 positive cells are TA 
cells and retain clonogenic capacity, they may be capable of multiple rounds of division 
and contribute to tumor development. Notably, it has been reported that several murine 
tumors including retinoblastoma, prostate and mammary gland tumors and chronic 
myeloid leukemia showed high Sca-1 expression levels that correlated with a highly 
malignant phenotype (91, 106, 89, 23, 22). In the prostate, Akt overexpression in Sca-1 
positive cells initiates tumorigenesis, with cancer progression correlating with increased 
Sca-1 cells (22). In preliminary analyses, an increase in Sca-1 positive cells was 
observed in the skin tumors obtained from BK5.Stat3C mice subjected to the two-stage 
skin carcinogenesis protocol (D.Rao and J.DiGiovanni, unpublished studies). 
Studies are currently underway to test if Sca-1 positive cells are directly involved in skin 
tumor development or tumor progression. 
  In conclusion, the current data demonstrate that Stat3 plays an important role in 
regulating the behavior of keratinocyte stem/progenitor cells found in the hair follicle. 
Stat3 overexpression led to increased stem cell maturation to progenitor/TA cell 
populations with attrition of the bulge region stem cell population (i.e., CD34+/α6+ /K15 
population). These changes appeared to be due to the effects of Stat3 on expression of 
multiple genes, including Sca-1, c-Myc, Twist and several other EMT related genes 
(e.g. Twist). Stat3 deletion on the other hand led to increased differentiation of IFE 
keratinocytes, which was further enhanced, with TPA treatment. Stat3 deletion also led 
to decreased survival and proliferation of keratinocytes especially those located in the 
bulge region of the hair follicle. Further study of the effects of Stat3 activation on KSCs 
and other keratinocyte cell populations will lead to a better understanding of how this 
transcription factor contributes to tumor development and progression.   
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Chapter 9 
Ongoing/Future Studies and Significance 
1. Twist as a Stat3 target gene 
Twist has been identified as one of the genes that promotes metastasis in vivo 
and induces EMT and increased cell survival in vitro (107). It was also found to be 
upregulated and overexpressed in a number of human tumors including breast cancer, 
prostate cancer, glioma, melanoma etc (108). A number of downstream effectors of 
Twist are known but until recently the molecular mechanisms underlying the 
upregulation of Twist in cancers was not clearly determined. Cheng GZ et al reported 
that activation of Stat3 induced Twist expression and inhibiting Stat3 by multiple 
techniques including use of a small molecule Stat3 inhibitor or Stat3 specific shRNA or 
using a dominant negative Stat3, which inhibited the expression of Stat3. In addition, 
these studies revealed five putative Stat3 binding sites on the Twist promoter and also 
show that Stat3 regulates Twist expression by directly binding to the promoter region of 
Twist (99).  
 
2. Role of Twist in tumor progression 
Twist, a transcription factor, regulates a number of functions that include cell 
motility and tissue reorganization during embryogenesis. Like a number of other 
molecules, in addition to its function during development, Twist plays critical roles 
during tumorigenesis too. Twist is known to be more important during tumor progression 
but does not significantly alter the ability of cancer cells to develop primary tumors. 
Notably, reduced expression of Twist led to decreased metastasis especially in 
mammary carcinoma cell lines in vivo (109). It is now known that Twist in association 
with the other core EMT factors like Snail and Slug acts cooperatively to form an EMT 
signaling network (110). It has also been reported that Twist acts as a master regulator 
and modulates expression of multiple important targets to promote EMT, E-cadherin 
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being one of them. Loss of E-cadherin is one of the critical features of EMT, which is 
mediated through the E-boxes in its promoter region that results in silencing its 
transcription. Twist was shown to bind to the E-boxes in the E-cadherin promoter 
region, which led to transcriptional repression of E-cadherin. However, rescue 
experiments indicate that, E-cadherin is not the only target that Twist modulates to 
induce an EMT phenotype in cells (107). 
Studies done in our lab with the BK5.Stat3C mouse model of skin 
carcinogenesis have shown Twist upregulation at the mRNA level in normal 
keratinocytes (see Figure 23) and at the protein level in skin tumors of these transgenic 
mice (86). These data suggest that Twist may be one of the Stat3 targets that mediate 
migration of keratinocytes and increased invasive response in the tumors in BK5.Stat3C 
transgenic mice. In this regard, we are currently generating a trigenic mouse line 
BK5.Stat3C X K5.Cre X Twistfl/fl  which generates mice that are both deficient in Twist 
and constitutively express Stat3 in the K5 expressing compartment of the skin that 
includes the keratinocytes in the epidermal basal layer as well as the ORS of the hair 
follicle (see Figure 29 for breeding scheme). We expect to see reduced tumor 
progression in these mice that constitutively express Stat3C and are deficient in Twist. 
These studies could help identify an important target gene for preclinical and 
clinical testing. Targeting genes like Twist that are known to play critical roles during the 
tumor progression phase of skin carcinogenesis would be an important step towards 
identifying drug targets that could ultimately be used for therapy. 	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Breeding Scheme to develop BK5.Stat3C X K5.Cre(+/-)  X  Twistfl/fl  trigenic mouse 
Figure 29: Breeding scheme to generate mice that are Twist deficient and 
express constitutively active Stat3.  Stat3C mice were crossed with Twistfl/fl  mice 
and subsequently crossed with K5.Cre mice to obtain mice that are both deficient in 
Twist and constitutively express Stat3. 
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3. Survivin, another Stat3 target gene	  
Survivin, is one of the smallest IAP and is a 16.5kDa protein. Survivin’s role in 
anti-apoptosis has been now very well established but it is also speculated that Survivin 
is involved in mitosis. One of the most interesting features of Survivin is its differential 
expression in various tissues. Survivin is strongly expressed in embryonic tissue but is 
rarely expressed in adult tissues. However, Survivin expression is dramatically 
upregulated in proliferating tissues and in a number of different tumors that include lung, 
breast, gastric, pancreas, ovary, liver, neuronal, gastric tumors and melanoma. Survivin 
is not expressed in the keratinocytes in the basal layer of the murine skin.  
A number of studies have now showed that Survivin is one of the Stat3 target genes. 
Constitutive activation of Stat3 led to Survivin upregulation in gastric cancer cells (111). 
Downregulation of Stat3 led to a decrease in Survivin expression in pancreatic cancer 
cells (112). However, it still remains undetermined if Stat3 directly binds to the promoter 
region of Survivin and regulates its transcriptional activity. Preliminary studies done in 
our lab show Survivin expression in K15 expressing cells in the bulge region of the hair 
follicle in BK5.Stat3C mice (see Figure 30). The role of Survivin in mouse skin is very 
unclear. Studies are currently underway in our lab to study the impact of Survivin in 
murine skin especially during skin tumorigenesis. These studies will reveal the 
downstream targets of Stat3 that mediate its biological roles especially during skin 
carcinogenesis.  In addition, these studies will also help answer the role of Survivin in 
specific stages of the multistage carcinogenesis bioassay. 
It is very important to identify genes or proteins that may play a role in tumor 
development and progression since that will help identify drug targets that can be used 
for therapy. In addition, it also helps develop chemo-preventive strategies for molecules 
that may be aberrantly expressed in cancers. 
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Figure 30: Survivin expression in the bulge region of the hair follicle of 
BK5.Stat3C transgenic mice. Formalin fixed, paraffin embedded skin sections from 
BK5.Stat3C mice were immunostained for Survivin and K15 expression and observed 
by confocal microscopy. 
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